Official Title of Study:  
An Open -Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs  
Standard of Care Therapy for First -Line Treatment of Metastatic Colorectal Cancer  
(CheckMate 9X8: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 9X8)  
 
Study ID: [REMOVED] 
Document Date (Date in which document was last revised): November 13 , 2020 
Page: 1
Protocol Number: CA2099X8
IND Number: 119,381
EUDRACT Number: 2017-003662-27
Date: 13-Oct-2017
Revised Date: 13-Nov-2020
Clinical Protocol CA2099X8
An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs 
Standard of Care Therapy for First-Line Treatment of Metastatic  Colorectal Cancer 
(CheckMate 9X8: CHECKpoint pathway and nivoluMab clinical Trial  Evaluation 9X8)
Protocol Amendment 07
Incorporates Administrative Letter 05
24-hr Emergency Telephone Number
Bristol-Myers Squibb Company
3401 Princeton Pike
Lawrenceville, NJ 08648
Avenue de Finlande 4
B-1420 Braine-l’Alleud, Belgium
This document is the confidential and proprietary information of Bristol-Myers Squibb 
Company and its global affiliates (BMS). By reviewing this document, you agree to keep it 
confidential and to use and disclose it solely for the purpose of assessing whether your 
organization will participate in and/or the performance of the proposed BMS sponsored 
study. Any permitted disclosures will be made only on a confide ntial "need to know" basis 
within your organiz ation or to your independent ethics committe e(s). Any other use, copying, 
disclosure or dissemination of this information is strictly prohibited unless expressly 
authorized in writing by BMS. Any supplemental information (eg,  amendments) that may 
be added to this document is also confidential and proprietary to BMS and must be kept in 
confidence in the same manner as the contents of this document.  Any person who receives 
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 2this document without due authorization from BMS is requested t o return it to BMS or 
promptly destroy it. All other rights reserved. References to BMS in this protocol may apply 
to partners to which BMS has transferred obligations, eg, a Contract Research Organization 
(CRO).
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 3DOCUMENT HISTORY
Document Date of Issue Summary of Change
Protocol
Amendment 0713-Nov-2020
Administrative 
Letter 0528-Sep-2020
Revised Protocol 
0602-Jun-2020Major change: Clarifies study treatment duration for standard of  care 
(SOC)
SOC may continue, after the maximum treatment duration of 24 mo nths 
for nivolumab, until progression, unacceptable toxicity, withdr awal of 
consent, or the end of the study, whichever comes first.
Revised Protocol 
0519-Dec-2019 This revised protocol removes Interim Analysis 2 (IA 2).
Revised Protocol 
0407-Dec-2018Clarifies the infusion days for fluorouracil, updates Appendix 3,  and 
aligns Appendix 4 with contraceptive guidance for nivolumab and  other 
components of study treatment.
Revised Protocol 
0313-Sep-2018Incorporates Administrative Letter 03, and reinstates exclusion criteria 
2j.
Administrative 
Letter 0311-Sep-2018 Adding Appendix 11 back into the document
Revised Protocol 
0206-Aug-2018Incorporates Administrative Letter 02 and updates to be consiste nt with 
SmPC and label information. Revises prohibited and/or restricted 
treatments; laboratory tests, assessments, and other analyses; dose modification criteria; urinalysis  sample collect ion 
requirements.  clarifie s 
eligibility criteria.  
 Minor changes and corrections including revisions to reflect the 
most recent language for BMS studies.
Administrative 
Letter 0223-Apr-2018
Revised Protocol 
0102-Feb-2018Incorporates Administrative Letter 01, revisions to laboratory tests 
exclusion criteria, revisions to dose modification criteria, urinalysis  
 sample collection requirements.  
 Addition of a definit ion of 
DILI for participants with elevated liver function tests at baseline. Updated rationale for the 2-year treatment duration, in additio n of a 
number of other minor changes and corrections.
Administrative 
Letter 0107-Dec-2017
Original Protocol 13-Oct-2017 Not applicable
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 4
Approved 9.0 v
Approved
1.0
v

TABLE OF CONTENTS
TITLE PAGE................................................................................................................
DOCUMENT HISTORY .............................................. ................................................
SUMMARY OF KEY CHANGES OF PROTOCOL AMENDMENT 07 ............... ...
TABLE OF CONTENTS..............................................................................................
1 SYNOPSIS.................................................... .............................................................
2 SCHEDULE OF ACTIVITIES..................................................................................
3 INTRODUCTION ................................................ .....................................................
3.1.1 Research Hypothesis ................................................................................ 
4 OBJECTIVES AND ENDPOINTS .................................... .......................................
5 STUDY DESIGN.......................................................................................................
5.1 Overall Design ............................................ ......................................................
5.1.2 Blinded Independent Central Review ....................................................... 
5.2 Number of Participants .....................................................................................
5.3 End of Study Definition................................... .................................................
6 STUDY POPULATION ............................................................................................
6.1 Inclusion Criteria ..............................................................................................
6.2 Exclusion Criteria ........................................ .....................................................
6.3 Lifestyle Restrictions ........................................................................................
6.4 Screen Failures........................................... .......................................................1
3
4
5
8
15
25
25
36
37
37
41
41
41
46
4648
50
50&lLnLcal Protocol
%06-936558&A2099;8
nLvolXmaE
Protocol Amendment No.: 07Date: 13-Nov-2020 5
Approved 9.0 v
Approved
1.0
v

6.4.1 Retesting During Screening ..................................................................... 
7 TREATMENT ................................................... ........................................................
7.1 Treatments Administered................................... ...............................................
7.2 Method of Treatment Assignment ............................ ........................................
7.4 Dosage Modification....................................... ..................................................
7.4.1 Nivolumab Dose Delay ............................................................................ 
7.4.2 Dose Modification Criteria for Oxaliplatin-Plus-Fluoropyrimidine 
Treatment .................................................................................................... 
7.4.2.1 General Guidance for Dose Modification for Chemotherapy ........ 
7.4.3 Dose Modification Criteria for mFOLFOX6 ........................................... 
7.4.4 Dose Modification Criteria for bevacizumab .......................................... 
7.4.5 Treatment of Infusion-Related Reactions ................................................. 
7.5 Preparation/Handling/Storage/Accountability............... ...................................
7.6 Treatment Compliance...................................... ................................................
7.7 Concomitant Therapy........................................ ................................................
7.7.1 Prohibited and/or Restricted Treatments................................................. 
7.7.2 Other Restrictions and Precautions ......................................................... 
7.7.3 Permitted Therapy ................................................................................... 
7.7.3.1 Imaging Restriction and Precautions ............................................. 
7.8 Post-Study Drug Access ...................................................................................
8 DISCONTINUATION CRITERIA ...........................................................................
8.1 Discontinuation from Study Treatment ............................................................
8.1.1 Nivolumab Dose Discontinuation ............................................................ 
8.1.2 SOC Dose Discontinuation ...................................................................... 
8.1.3 Criteria to Resume Treatment with Nivolumab ....................................... 
8.1.4 Post Study Treatment Study Follow-up.................................................... 
8.2 Discontinuation from the Study............................ ............................................
8.3 Lost to Follow-Up......................................... ....................................................
9 STUDY ASSESSMENTS AND PROCEDURES............................ .........................
9.1 Efficacy Assessments ........................................................................................
9.1.1 Imaging Assessment for the Study............................................................ 
9.1.1.1 Methods of Measurement ................................................................ 
9.1.1.2 BICR Assessment of Progression .................................................... 
9.2 Adverse Events .................................................................................................
9.2.1 Time Period and Frequency for Collecting AE and SAE Information .... 
9.2.2 Method of Detecting AEs and SAEs ......................................................... 
9.2.3 Follow-up of AEs and SAEs ..................................................................... 
9.2.4 Regulatory Reporting Requirements for SAEs ......................................... 
9.2.5 Pregnancy ................................................................................................ 
9.2.6 Laboratory Test Result Abnormalities ..................................................... 
9.2.7 Potential Drug Induced Liver Injury (DILI) ............................................ 
9.2.8 Other Safety Considerations .................................................................... 
9.3 Overdose .................................................. .........................................................50
51
53
55
56
56
56
57
5758
59
60
61
61
61
61
62
6262
62
62
63
6566
67
67
67
6869
69
69
70
71
72
73
73
7373
74
74
75
75&lLnLcal Protocol
%06-936558&A2099;8
nLvolXmaE
Protocol Amendment No.: 07Date: 13-Nov-2020 6
Approved 9.0 v
Approved
1.0
v

9.4 Safety ................................................................................................................
9.4.1 Physical Examinations ............................................................................. 
9.4.2 Vital signs................................................................................................. 
9.4.3 Clinical Safety Laboratory Assessments .................................................. 
9.4.4 Imaging Safety Assessment ...................................................................... 
10.2 Populations for Analyses ................................. ...............................................
10.3 Statistical Analyses .........................................................................................
10.3.1 Efficacy Analyses ................................................................................... 
10.3.2 Safety Analyses....................................................................................... 
10.3.4 Interim Analyses ..................................................................................... 
12 APPENDICES ................................................. ........................................................
APPENDIX 1 ABBREVIATIONS AND TRADEMARKS ....................... .................
APPENDIX 2 STUDY GOVERNANCE CONSIDERATIONS .................... .............
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS:
DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATING,
FOLLOW UP AND REPORTING....................................... ..................................
APPENDIX 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND
METHODS OF CONTRACEPTION.....................................................................
DEFINITIONS................................................... ...........................................................
APPENDIX 5 NIVOLUMAB MANAGEMENT ALGORITHMS .................... .........
APPENDIX 6 ECOG PERFORMANCE STATUS .....................................................
APPENDIX 7 RECIST 1.1 GUIDELINES ..........
APPENDIX 10 COUNTRY SPECIFIC APPENDIX...................................................
APPENDIX 11 REVISED PROTOCOL SUMMARY OF CHANGE HISTORY......
 75
75
75
76
76
82
82
82
84
84
95
96
100
108
112
112
115
124
125
136
137&lLnLcal Protocol
%06-936558&A2099;8
nLvolXmaE
Protocol Amendment No.: 07Date: 13-Nov-2020 7
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
1 SYNOPSIS
Protocol Title: An Open-Label Exploratory Phase 2/3 Study of Niv olumab with Standard of 
Care Therapy vs Standard of Care Therapy for First-Line Treatme nt of Metastatic 
Colorectal Cancer 
(CheckMate 9X8: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 9X8)
Study Phase: 2/3
CA209-9X8 (CHECKpoint pathway and nivoluMAB clinical trial eval uation 9X8) is a Phase 2/3, 
open-label, multi-center trial to evaluate nivolumab in combina tion with standard of care (SOC) 
therapy (mFOLFOX6) with bevacizu mab for the treatment of first- line metastatic color ectal cancer 
(mCRC)1. 
Study Population:
Male a
nd female participan ts of 18 years of age or more with fi rst-line histologically confirmed 
metastatic colorectal cancer, not amenable to curative resectio n.
Protocol Amendment No.: 07
Date: 13-Nov-2020 8
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Objectives and Endpoints:
Objectives Endpoints
Primary
•To compare the efficacy of nivolumab plus SOC 
chemotherapy with bevacizumab (Nivo+SOC) with SOC chemotherapy with bevacizumab (SOC) in participants with mCRC•Progression Free Survival (PFS) by BICR 
Secondary
•To evaluate preliminary efficacy in all randomized participants•ORR, DCR, DoR, TTR by BICR per RECIST v1.1
•ORR, PFS, DCR, DoR, TTR by investigator per RECIST v1.1
•OS
•To characterize the safety and tolerability of nivolumab in combination with standard therapy with bevacizumab•Safety (including but not limited to): Incidence of AEs, SAEs, deaths, and clinical abnormalities per CTCAE (Version 4)
Protocol Amendment No.: 07
Date: 13-Nov-2020 9
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Objectives Endpoints
AEs, adverse events; BICR, blinded independent central review; D CR, disease control rate; DoR, duration of res ponse; 
 
     
OS, over all survival; ORR, objective respo nse rate;  
 SOC, standard  of care;  
TTR, time to response; . 
Overall Design:
This is a Phase 2/3 open-label, multi-center trial of nivolumab  in combination with SOC first-line 
chemotherapy with bevacizumab to evaluate the safety profile and  clinical activity of this regimen 
in participants with treatment-naive metastatic colorectal cance r (mCRC).  
In Phase 2, participants will be randomized to treatment with m FOLFOX6 + bevacizumab with or 
without nivolumab.  
 
 
Participants will be treated until progression, unacceptable to xicity, withdrawal of consent, or the 
end of the study, whichever comes first. Nivolumab will be give n for a maximum of 24 months.
Protocol Amendment No.: 07
Date: 13-Nov-2020 10
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Figure 1: Study Design
DCR, disease control rate; FA; final analysis; IA, interim anal ysis; ORR, objective response rate; OS, overall survival; 
PFS, progression-free survival.
bDepending on the results at the time of interim analysis (IA), d ifferent possible decisions may be made as indicated 
by dashed arrows. If there is not en ough evidence of favorable benefit/risk at IA, the Phase 2 stud y will continue to 
complete with 180 participants unless unacceptable safety conce rn arises.
One interim analysis (IA) is pla nned in Phase 2 portion of the st udy to  
.
 
 The 
interim results will guide the following decisions:
•When a strong efficacy signal is observed for all ra ndomized participants,  
 is 
observed and no substantial differential effects by subgroups, t he study will expand  
. 
•Otherwise, the study continues as planned.
If there are  not enough data to support an internal decision at the time of IA, the study will continue 
to 180 randomized participants. 
Protocol Amendment No.: 07
Date: 13-Nov-2020 11
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Treatment Arms and Duration:
Study treatments
: 
Protocol Amendment No.: 07
Date: 13-Nov-2020 12
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Study Drug for CA2099X8
Medication Potency IP/Non-IP 
Nivolumaba
Solution for Injection100 mg (10 mg/ml) and 
40 mg (10 mg/ml)IP
Oxaliplatinb various strengths IP
ቄLeucovorin
CalciumFolinateቅb various strengths IP
Fluorouracilb various strengths IP
Bevacizumabb various strengths IP
aMay be labeled as either ͆BMS-936558-01 ͇or ͆Nivolumab ͇
bThese products may be obtained by the investigational s ites as lo cal commercial products in certain countries if 
allowed by local regulations. 
Protocol Amendment No.: 07
Date: 13-Nov-2020 13
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 14
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
2 SCHEDULE OF ACTIVITIES
Table 2-1: Screening Procedural Outline (CA2099X8)
Procedurea Screening 
VisitNotes
Eligibility Assessments
Informed Consent XRegister in Interactive Response system to obtain participant nu mber.
Must be obtained prior to performing any protocol related scree ning procedures.
Study allows for re-enrollment of a participant that has discontinued the study as a pre-
treatment failure. If re-enrolled, the participant must be re-c onsented and assigned a new 
participant number from IRT.
Inclusion/Exclusion Criteria XAll inclusion/exclusion criteria should be assessed at screenin g (re-enrollment if applicable) 
and confirmed prior to randomization.
Medical History X All medical history relevant to the disease und er study
Baseline Tumor Submission XEither a formalin-fixed, paraffin-embedded (FFPE) tissue block or unstained tumor tissue 
sections (minimum 20 slides from a metastatic site or 25 from a primary colon site), 
obtained within 180 days prior to enrollment and after the last dose of the most recent 
systemic anti-cancer therapy, with an associated pathology repo rt, must be submitted to the 
core laboratory for inclusion. For participants with samples ou tside of the above criteria, a 
fresh biopsy will be required. 
If the above sample is not from the primary colon tumor, an additional archival sample of at 
least 5 slides must be submitted from the primary colon tumor.  These five slides may be 
submitted after randomization.
Central lab must provide IRT with confirmation of receipt of evaluable tumor tissue prior to 
randomization. Biopsy should be excisional, incisional or core needle. Fine needle 
aspiration is unacceptable for submission.
Baseline Tumor Assessment XMust be performed within 28 days prior to first dose. Brain ima ging to be performed at 
screening for participants with a history or clinical symptoms of brain metastasis. Bone 
scan may be performed as clinically indicated. See Section 9.1.1
Protocol Amendment No.: 07
Date: 13-Nov-2020 15
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Table 2-1: Screening Procedural Outline (CA2099X8)
Procedurea Screening 
VisitNotes
Safety Assessments
Targeted Physical Examination, Measurements, 
Vital Signs and Performance StatusXHeight, weight, Performance Status (ECOG, see Appendix 6 ), BP, HR, Temperature. Must 
be collected within 14 days prior to randomization.
ECG X Within 14 days prior to randomization.
Assessment of Signs and Symptoms X Must be performed within 14 da ys prior to randomization.
Concomitant Medication Use XMust be collected within 14 days prior to randomization.
Vaccine use within 30 days prior to randomization.
SAE Assessment X Serious Adverse Event collection from time of con sent.
Laboratory Tests Includes blood and urine samples. 
CBC w/differential, Chemistry, Endocrine, Viral, urinalysisXCBC, chemistry, urinalysis and endocrine testing must be perform ed within 14 days prior to 
randomization.  Note: Laboratory tests do not need to be repeat ed on C1D1 if screening lab 
results are deemed still clinically valid by the treating invest igator.
Urinalysis or urine dipstick i ncluding protein, glucose, blood, leukocyte esterase, specific 
gravity, pHb
Viral testing to be performed within 28 days prior to randomiza tion. Refer to Section 9.4.3
for list of laboratory tests to conduct.
Pregnancy Test XFor WOCBP only: Serum or urine pregnancy test (minimum sensitiv ity 25 IU/L or 
equivalent units of HCG) to be done at screening visit and with in 24 hours prior to first 
dose of study therapy. See Appendix 4
For females under the age of 55, FSH > 40 mIU/mL is required to confirm menopause.
MMR/Microsatellite Status XConfirm availability of pathology report for MMR or microsatell ite-testing results. Report 
must contain MMR or microsatellite-testing results and should al so contain specific results 
per markers tested by IHC or PCR.
Please see inclusion criteria ( Section 6.1 )  for details.
Protocol Amendment No.: 07
Date: 13-Nov-2020 16
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Table 2-1: Screening Procedural Outline (CA2099X8)
Procedurea Screening 
VisitNotes
RAS and BRAF mutation Status XVerify RAS and BRAF mutation status, including Kirsten Rat Sarc oma (KRAS) and 
Neuroblastoma Rat Sarcoma (NRAS), based on local testing 
CEA (and CA19-9) Assessment XCEA tumor marker will be assessed at screening. If CEA is withi n normal limits, a CA19-9 
tumor marker will be checked. If the CA19-9 is elevated, this patient will be followed with 
the CA19-9 AND CEA tumor markers . However, if the CA19-9 is withi n normal limits, 
this patient will be followed with CEA tumor marker only.
BP, blood pressure; CA19-9, cancer antigen 19-9; CBC, complete b lood count; CEA, carcino embryonic antigen; HR, heart rate; MMR, mismatch repair; SAEs, 
serious adverse events.
aSome of the assessments referred to in this section may not be captured as data in the eCRF. They are intended to be used as s afety monitoring by the treating 
physician. Additional testing or assessments may be performed as  clinically necessary or where required by institutional or local regulations
bUrinalysis or urine dipstick. If blood, protein, or leukocytes esterase are positive on the dipstick, microscopic examination of the sediment is required. If urine 
protein is ≥ 2+ from urine dipstick or equivalent from random u rinalysis, results from a 24-hour urine collection or urine pro tein to creatinine ratio (UPCR) are 
required to determine eligibility (refer to exclusion criteria) .
Protocol Amendment No.: 07
Date: 13-Nov-2020 17
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Table 2-2: On-Treatment Procedural Outline (CA2099X8)
ProcedureaCycle 1 (1 cycle = 4 weeks)b Each Subsequent Cycle
(cycle = 4 weeks)
Notes
D1 D2 D15 D16 D1 D2 D15 D16
Safety Assessments
Targeted Physical 
Examination, 
Measurements, Vital Signs, Performance StatusX   X X   X Weight, BP, HR, Temperature and Performance Status
Adverse Events Assessment (including SAEs)Continuously Record at each visit
Concomitant Medication Continuously Record at each visit
Laboratory Tests
Pregnancy Test X See notesSerum or urine pregnancy test to be done within 24 hours 
prior to first dose, and then every 4 weeks ( ±7 days) 
regardless of dosing schedule. See Appendix 4.
CBC w/differential, Chemistry panel and 
urinalysisXX XXLaboratory assessments should be performed within 72 hours 
prior to each infusion.
Urinalysis or urine dipstick including protein, glucose, blood,  
leukocyte esterase, specific gravity, pH to be performed 
within 72 hrs prior to each bevacizumab infusiond.
Refer to Section 9.4.3
Thyroid Testing X X Refer to Section 9.4.3
CEA (and CA19-9)AssessmentX See notesSelected tumor marker(s) at screening (CEA alone or CEA 
and CA19-9) will be assessed eve ry 2 weeks (±7 days) until 
Week 12, then every 8 weeks (±7 days) thereafter, prior to 
each restaging.
Protocol Amendment No.: 07
Date: 13-Nov-2020 18
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Table 2-2: On-Treatment Procedural Outline (CA2099X8)
ProcedureaCycle 1 (1 cycle = 4 weeks)b Each Subsequent Cycle
(cycle = 4 weeks)
Notes
D1 D2 D15 D16 D1 D2 D15 D16
Efficacy Assessments
Tumor assessmentsImaging will begin at Week 12 (± 7 days) from randomization, 
and then every 8 weeks (± 7 days ) thereafter until confirmed 
progression, withdrawal of consent, or the study ends, 
whichever occurs first. This schedule should be followed even if 
treatment delay occurs. 
Brain Imaging See Section 9.1.1
Protocol Amendment No.: 07
Date: 13-Nov-2020 19
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Table 2-2: On-Treatment Procedural Outline (CA2099X8)
ProcedureaCycle 1 (1 cycle = 4 weeks)b Each Subsequent Cycle
(cycle = 4 weeks)
Notes
D1 D2 D15 D16 D1 D2 D15 D16
IRT Vial Assignment
Protocol Amendment No.: 07
Date: 13-Nov-2020 20
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Table 2-2: On-Treatment Procedural Outline (CA2099X8)
ProcedureaCycle 1 (1 cycle = 4 weeks)b Each Subsequent Cycle
(cycle = 4 weeks)
Notes
D1 D2 D15 D16 D1 D2 D15 D16
Randomization XRandomization after eligibility is confirmed. First treatment 
should occur within 3 calendar days of randomization.
Dispense Study 
Treatment:
Nivolumab 240 mg flat dose (Arm A) IVX X X X ONLY in ARM A (Nivolumab + SOC) 
Oxaliplatin 85 mg/m2IV X X X X
Leucovorin 400 or 350 
mg/m2  IVc XX X X
Fluorouracil 400 mg /m2
IVXX X X
Fluorouracil 1200 mg/m2
IVc XX XXContinuous infusion over 24 hours. Day 1 (or Day 15) 
through Day 2 (or Day 16) of each cycle (total dose of 
2400 mg/m2over 48 hours)
OR
Fluorouracil 2400 
mg/m2IVcXX XXContinuous infusion over 46 to 48 hours. Day 1 (or Day 15)
through Day 2 (or Day 16)
Bevacizumab 5 mg/kg IV X X X X
BP, blood pressure; CA19-9, cancer antigen 19-9; CBC, complete b lood c ount; CEA, car cino embryonic antigen; HR, heart rate;  IRT, 
interactive response technology; SAEs, seri ous adverse events.
Note: All scheduled clinic visits are to occur within ±3 days of scheduled day.
aSome of the assessments referred to in this section may not be c aptured as data in the eCRF. They are intended to be used as sa fety monitoring by the treating 
physician. Additional testing or assessments may be performed as clinically necessary or where required by institutional or lo cal regulations
Protocol Amendment No.: 07
Date: 13-Nov-2020 21
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
bIf a dose is delayed, the procedures schedule for that same tim epoint should also be delayed to coincide with when that timepo int’s dosing actually occurs. If 
dose is delayed, CEA (and CA19-9) schedule should be kept regardless of dosing.
cRegimen for FOLFOX6 may be used as per local standards
dIf urine protein is ≥ 2+ from urine dipstick or equivalent from  random urinalysis a 24 hour urine collection or UPCR should be pe rformed and results obtained 
before the next treatment with bevacizumab.  See  Section 7.4.4 for bevacizumab dose modification criteria.
Protocol Amendment No.: 07
Date: 13-Nov-2020 22
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Table 2-3: Follow-up Procedural Outline (CA2099X8)
ProcedureaSafety 
Follow-
up visits 
1 and 2bSurvivalFollow-up
c Notes
Safety Assessments
Targeted Physical Examination, Vital Signs X
Adverse Events Assessment (including SAEs) XParticipants will be followed for treatment related toxicities until these 
toxicities resolve, return to baseline, or are deemed irreversible. All 
adverse events will be documented for a minimum of 100 days after last 
dose.
(See Appendix 3)
Concomitant Medication Review X
Review of Subsequent Cancer Therapies X XAdditional subsequent cancer therapy details such as regimen, setting of 
the regimen, line of therapy, start date and end date of each r egimen, best 
response to the regimen and date of progression after second line therapy 
will be collected.
Laboratory Tests
Pregnancy Test X
CBC w/differential, Chemistry panel, Thyroid testing, 
and urinalysisXTo be done at safety follo w-up visit 1. To be repeated at safety follo w-up 
visit 2 if study related toxicity persists.
FU visit 1 ONLY:  Urinalysis or urine dipstick including protein, glucose, 
blood, leukocyte esterase, specific gravity, pHd
Refer to Section 9.4.3 Clinical Safety Laboratory Assessments for list of 
laboratory tests.
Efficacy Assessments
Tumor assessmentsParticipants who enter the follow-up period without tumor progre ssion will continue to have tumor 
imaging assessments as per on-treatment schedule (at Week 12 fr om randomization, and then every 8 
weeks thereafter until confirmed progression, withdrawal of consent, or the study ends, whichever 
occurs first). 
Protocol Amendment No.: 07
Date: 13-Nov-2020 23
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Table 2-3: Follow-up Procedural Outline (CA2099X8)
ProcedureaSafety 
Follow-
up visits 
1 and 2bSurvivalFollow-up
c Notes
Brain Imaging See Section 9.1.1
Participant Status
Survival status X XEvery 3 months after safety follow-up visit 2; may be accomplis hed by 
visit, phone contact or email, to assess subsequent anti-cancer  therapy for 
up to 3 years after completing safety follow up visit in all coho rts.
CBC, complete bl ood count; SAEs, serious a dverse events;  
.
Note: All scheduled clinic visits are to occur within ±3 days of scheduled day.
aSome of the assessments referred to in this section may not be captured as data in the eCRF. They are intended to be used as s afety monitoring by the treating 
physician. Additional testing or assessments may be performed a s clinically necessary or where required by institutional or lo cal regulations
bParticipants must be followed for at least 100 days after last d ose of study treatment. Follow-up visit 1 (FU1) = 30 days from the last dose ( ±7 days) or coincides 
with the date of discontinuation ( ±7 days) if date of discontinuation is greater than 42 days afte r last dose, Follow-up visit 2 (FU2) = 100 days (± 7 days) from 
last dose. Both Follow Up visits should be conducted in person.
cSurvival Follow-up visits  to occur every 3 months ( ±14 days) from Follow-up visit #2. Survival visit may be conduct ed in person or by telephone. BMS may 
request that survival data be collected on all treated particip ants outside of the 3 month specified window. At the time of th is request, each participant will be 
contacted to determine their survival status unless the particip ant has withdrawn consent for all contact.
dUrinalysis or urine dipstick. If blood, protein, or leukocytes esterase are positive on the dipstick, microscopic examination o f the sediment is required. If urine 
protein is ≥ 2+ from urine dipstick or equivalent from random ur inalysis, 24-hour urine collection or UPCR may be performed if deemed clinically indicated by 
the investigator.
Protocol Amendment No.: 07
Date: 13-Nov-2020 24
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
3 INTRODUCTION
CA209-9X8 (CHECKpoint pathway and nivoluMAB clinical trial eval uation 9X8) is a Phase 2/3,
open-label, multi-center trial to evaluate nivolumab (BMS-936558) in combination with standard 
of care (SOC) chemotherapy (mFOLFOX6) with bevacizumab for the treatment of first-line
metastatic colorectal cancer (mCRC)1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.1
Research Hypothesis
Nivolumab plus SOC chemotherapy with bevacizumab (Nivo + SOC) wil l demonstrate superior 
efficacy (defined as progression-free survival [PFS]) compared to SOC chemotherapy with 
bevacizumab alone in participants with previously untreated mCR C.  
 
Protocol Amendment No.: 07
Date: 13-Nov-2020 25
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 26
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 27
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 28
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 29
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 30
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 31
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 32
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Amendment No.: 07
Date: 13-Nov-2020 33
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 34
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Date: 13-Nov-2020 35
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
4 OBJECTIVES AND ENDPOI
NTS
Table 4-1: Objectives and Endpoints
Objectives Endpoints
Primary
•To compare the efficacy of nivolumab plus standard of care (SOC )
chemotherapy with bevacizumab (Nivo + SOC) with SOC chemotherapy 
with bevacizumab in participants with mCRC•Progression Free Survival(PFS) by BICR 
Secondary
•To evaluate preliminary efficacy in all randomized participants •ORR, DCR, DoR, TTR by BICR pe r RECIST v1.1
•ORR, PFS, DCR, DoR, TTR by investigator per RECIST v1.1
•OS
•To characterize the safety and tolerability of nivolumab in com bination 
with standard therapy with bevacizumab•Safety (including but not limited to): incidence of AEs, 
SAEs, deaths, and clinical 
abnormalities per CTCAE (Version 4)
Protocol Amendment No.: 07
Date: 13-Nov-2020 36
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Table 4-1: Objectives and Endpoints
Objectives Endpoints
AEs, adverse events; BICR, blinded independent central review; D CR, disease control rate; DoR, duration of res ponse; 
 
       
OS, over all survival; O RR, objectiv e response rate; PFS, progression-free survival;  
 SOC, standard  of care;  
TTR, time to response; . 
5 STUDY DESIGN
5.1 Overall Design
This is a Phase 2/3, randomized, open-label study of nivolumab p lus SOC, or SOC alone, in the 
first-line treatment of participants with metastatic CRC. 
Protocol Amendment No.: 07
Date: 13-Nov-2020 37
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
 
 
T
he study design schematic is presented in  Figure 5.1-1.
Figure 5.1-1: Study Design Schematic
DCR, disease control rate; FA; final analysis; IA, interim anal ysis; ORR, objective response rate; OS, overall survival; 
PFS, progression-free survival.
 
bDepending on the results at the time of interim analysis (IA), different possible decisions may be made as indicated 
by dashed arrows. If there is not en ough evidence of favorable benefit/risk at IA, the Phase 2 stud y will continue to 
complete with 180 participants unless unacceptable safety conce rns arise.
One interim analysis (IA) is planned in the Phase 2 portion of th e study  
.
 
The interim 
results will guide the following decisions:
•When a strong efficacy signal is observed for all ra ndomized participants,  
 is 
Protocol Amendment No.: 07
Date: 13-Nov-2020 38
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
observed and no substantial differential effects by subgroups, t he study will expand  
. 
•If the study does not expand at IA, enrollment continues as pla nned.
If there are not adequate data to support expanding the study at t he time of IA, the study will 
continue to 180 randomized participants. 
This study will consist of three phases: screening, treatment, and follow-up. For a complete list of 
study required procedures, please refer to  Section 2 .
Screening Phase
Screening begins by establishi ng the particip ant’s initial elig ibility and signing of the informed 
consent (ICF). Participant is e nrolled using the Interactive Response Technology (IRT) system.
Participant is assessed for study eligibility according to the inclusion ( Section 6.1 ) and exclusion 
(Section 6.2 ) criteria.  Completion of screening assessments must be complet ed in accordance with 
timelines as indicated in Table 2-1.  The pathological reports confirming eligibility must be
reviewed, dated, and signed by the investigator prior to random ization.
Participants must submit mandatory baseline tumor sample:
•Either a formalin-fixed, paraffin-embedded (FFPE) tissue block or unstained tumor tissue 
sections (minimum 20 slides from metastatic site or 25 from prima ry colon tumor), obtained
within 180 days prior to enrollment and after the last dose of the most recent systemic anti-
cancer therapy, with an associated pathology report, must be su bmitted to the core laboratory 
for inclusion. For participants with samples outside of the above criteria, a fresh biopsy will be 
required. Central lab must pr ovide IRT with confirmation of rec eipt of evaluable tumor tissue 
prior to randomization. Biopsy should be excisional, incisional  or core needle. Fine needle 
aspiration is unacceptable for submission.
•In addition, at least 5 slides from the pr imary colon tumor must be submitted if the above 
specimen is from a metastatic site. The 5 slides from the prima ry tumor may be submitted after 
randomization.
The screening phase either ends with confirmation of full eligibility and rando mization for the 
participants, or with the confirmation that the participant is a screen failure. This study permits the 
re-enrollment of a participant that has discontinued the study as a pre-treatment failure prior to 
randomization. If re-e nrolled, the par ticipant must be re-consented. A new participant 
identification number will be  assigned by IRT at the time of re -enrollment.
Treatment Phase
Following confirmation of eligibility, tr eatment phase begins with the treatment assignment call 
to the IRT. Participants will be randomized 2:1 to one of the f ollowing treatment arms:
•Arm A: nivolumab plus SOC (Nivo +SOC)
•Arm B: SOC
Protocol Amendment No.: 07
Date: 13-Nov-2020 39
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Administration of study treatment is to begin within 3 calendar d ays of randomization. Participants 
will receive study treatment, until progression , unacceptable to xicity, or withdrawal of consent, or 
the study ends, whichever occurs first. Nivolumab will be given for a maximum of 24 months.
Women of child bearing potential (WOCBP) must have a documented  negative pregnancy test 
within 24 hours pri or to the start of each dose of the investigational product. On- study vital sign 
assessments should be performed within 72 hours prior to the first dose and then prior to dosing. 
Please refer to Table 2-2. On-study laboratory assessments should be drawn within 72 hours prior 
to dosing and will be assessed at the local laboratory. Please refer to Table 2-2 .Tumor assessments 
will occur in accordance with  Table 2-2 until c onfirmed disease progressi on (by BICR). Each site 
should submit scans on a rolling basis and preferably withi n 7 days of image acquisition to a central 
vendor and report any pertinent cytology/pathology results for central review by the BICR. If 
progression (defined in Section 9.1.1 ) is assessed by the investigator, the site w ill inform the 
radiology vendor so that the BICR assessment/confirmation of pro gression can be performed.
Please refer to Section 9.1.1.2 for additional details.
•Participants whose progression is not confirmed by the BICR wil l be required to continue 
tumor assessments (if clinically feasible) according to the pro tocol-specified schedule or 
sooner if clinically indicated. Investigators are strongly enco uraged to wait for BICR 
confirmation of progression prior to initiating any subsequent t herapy. 
 
 
 
Treated participants will be evaluated for progression beginni ng 
at Week 12 ( ±7 days), and then every 8 weeks ( ±7 days) during treatment. Following initial 
progression, participants will continue t o be followe d during safety and survival follow  up.  
Treatment Phase ends 
when the participant is discontinued from study therapy. Please refer to Section 8.1 for a complete 
list of possible reasons for discontinuation. 
Follow-up Phase
Follow-up Phase begins after the decision is made to discontinu e a participant from study therapy 
(eg, due to toxicity,  progression, etc.). 
•Following initial progression, participants w ill conti nue to be followed during safety and 
survival follow up.  
Participants who enter the follow-up period without tumor progr ession will continue to have tumor 
imaging assessments per on-treatment schedule: at Week 12 ( ±7 days) from randomization and 
then every 8 weeks ( ±7 days).  
Protocol Amendment No.: 07
Date: 13-Nov-2020 40
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Pa rticipants will have 2 follow-up visits (FU1 
and FU2) for safety within approximately 100 days from the last  dose of study treatment. Both 
follow-up visits should be c onducted in person, according to Table 2-3 . Beyond this time period, 
participants will be followed for survival and ongoing tr eatment-related AEs un til these events 
have resolved, re turned to baseline or are d eemed irreversible. All toxicities will be documented 
for a minimum of 100 days after the last dose of study medicati on. 
After the Follow-up 2 Visit, all participants will be followed for survival status every 3 months 
(±14 days) until death, withdrawal of consent, lost to follow-up,  or end of study.
•Survival status may be ascertained by telephone contact if the participant is unable to return to 
the site for a visit. 
•If new anti-tumor therapy is initiated for either disease progression or a sec ondary malignancy 
at any time during this period, this and all other pertinent da ta obtained should be recorded on 
the appropriate Case Report Form (CRF).
5.1.2 Blinded Independent Central Review
A BICR will be utilized in this st udy for determination of BICR- assessed endpoints. Details of 
BICR procedures will be specified in the BICR Charter. Refer to Section 9.1.1 Imaging 
Assessment for the Study for further details.
5.2 Number of Participants
Approximately 180 (up to 450 depending on IA results) participa nts will be randomized in a 
2:1 ratio. Approximately 120 participants in the nivolumab + SOC arm (Arm A) and
approximately 60 in the SOC alone arm (Arm B).
5.3 End of Study Definition
The start of the trial is defined as the first visit for first participant screened. End of trial is defined 
as the last visit or scheduled procedure shown in the schedule of activities (see Section 2 ). Study 
completion is defined as the final date on which data for the p rimary endpoint was or is expected 
to be collected, if this is not the same.
Protocol Amendment No.: 07
Date: 13-Nov-2020 41
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Amendment No.: 07
Date: 13-Nov-2020 42
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Amendment No.: 07
Date: 13-Nov-2020 43
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 44
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Protocol Amendment No.: 07
Date: 13-Nov-2020 45
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
6 STUDY POPULATION
For entry
 into the study, the following criteria MUST be met.
6.1 Inclusion Criteria1) Signed Written Informed Consent
a) Participants must have signed and dated an IRB/IEC approved w ritten informed consent 
form in accordance with regulatory and institutional guidelines . This must be obtained 
before the performance of any protocol related procedures that are not part of normal 
participant care.
b) Participants must be willing and able to comply with schedule d visits, treatment schedule, 
laboratory tests, t umor biopsies , and other requirements of the  study.
2) Type of Participant and Target Disease Characteristics
a) Histologically confirmed metastatic colorectal cancer, not am enable to curative resection.
b) Available local test results for tumor BRAF, KRAS and NRAS (e xtended RAS) mutation 
status and Microsatellite/MMR testing in addition to available t umor sample as required 
per protocol (see 2(e))
c) No prior chemotherapy f or m etastatic colorectal cancer.  
i) If participant has received adjuvant or neoadjuvant chemother apy, there must be more 
than 6 months gap (> 6 months) between the completion of that t herapy and diagnosis 
of recurrent or metastatic disease.
d) Presence of measurable disease by RECIST 1.1 criteria.
i) Previously irradiated lesions may not be the target lesion unless there has been 
documented progression in those lesions
e) Adequate tumor tissue available.  Tumor tissue specimens:
i) Either a formalin-fixed, paraffin-embedded (FFPE) tissue bloc k or unstained tumor 
tissue sections (minimum 20 slides from a metastatic site or 25 from a primary colon 
site), obtained within 180 days prior to enrollment and after t he last dose of the most 
recent systemic anti-cancer therapy, with an associated patholo gy report, must be 
submitted to the core laboratory for inclusion. For participant s with samples outside of 
the above criteria, a fresh biopsy will be required. Biopsy sho uld be excisional, 
incisional or core needle. Fine needle aspiration is unacceptab le for submission.
ii) If the above sample is not from the primary colon tumor, an additional archival sample 
of at least 5 slides must be submitted from the primary colon tum or. These additional 
5 slides may be submitted after randomization.
iii) Central lab must confirm r eceipt of evaluable tumor ti ssue prior to randomization. 
Biopsies of bone lesions that do not have a soft tissue compone nt are also unacceptable 
for submission.
f) ECOG Performance Status of 0-1. See Appendix 7  for ECOG Performance Status scale.
Protocol Amendment No.: 07
Date: 13-Nov-2020 46
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
g) Re-enrollment: This study permits the re-enro llment of a participant that has discontinued 
the study as a pre-treatment f ailure (ie, participant has not b een treated). If re-enrolled, the 
participant must be re-consent ed and assigned a new participant  number from IRT.
h) All participants will be required to undergo mandatory on-stu dy biopsies. Participants will 
be required to undergo on-study biopsies at acceptable clinical risk as judged by the 
investigator in both arms.
i) The tumor tissue specimen must be a core needle biopsy, excis ional or incisional 
biopsy. Fine needle biopsies, drainage of pleural effusions wit h cytospins, or punch 
biopsies are not considered adequate . Biop sies of bone lesions 
that do not have a soft tissue component or decalcified bone tu mor samples are also not 
acceptable. Where possible, the biopsied lesion s hould be distinct from target lesions 
being evaluated for radiologic response, and when feasible the same lesion should be 
used for both the baseline and on-study sampling.
3) Age and Reproductive Status
a) Males and Females, ages ≥18 years of age
b) Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units  of HCG) within 24 hours 
prior to the start of study treatment.
c) Women must not be pregnant or breastfeedingd) Women of childbearing potential (WOCBP) randomized to the niv olumab + SOC arm must 
agree to follow instructions for method(s) of contraception (Appendix 4 ) for the duration 
of treatment with study treatment(s) and 6 months after the last d ose of study treatment.
e) Males randomized to the nivolumab + SOC arm who are sexually active with WOCBP 
must agree to follow instructions for method(s) of contraception ( Appendix 4 ) for the 
duration of treatment with study treatment(s) 7 months after th e last dose of nivolumab. In 
addition, male participants must be willing to refrain from spe rm donation during this time. 
f) Women of childbearing potential (WOCBP) randomized to the SOC  arm must agree to 
follow instructions for method(s) of contraception ( Appendix 4 ) for the duration of 
treatment with study treatment(s) and for at least 6 months afte r the last dose of 
investigational drug.
g) Males randomized to the SOC arm who are sexually active with WOCBP must agree to 
follow instructions for method(s) of contraception ( Appendix 4 ) for the duration of 
treatment with study treatment(s) and for at least 7 months afte r the last dose of 
investigational drug. In addition, male participants must be wi lling to refrain from sperm 
donation during this time. 
h) Azoospermic males are exempt from cont raceptive requir ements. WOCBP who are 
continuously not heterosexually active are also exempt from con traceptive requirements, 
and st ill must  undergo pregnancy testing as described in this section.
Investigators shall counsel WOCBP, and male participants who are sexually active with WOCBP, 
on the importance of pregnancy prevention and the implications of an unexpected pregnancy. 
Investigators shall advise on th e use of highly effective metho ds of contraception, ( Appendix 4 )
which have a failure rate of < 1% when used consistently and correctly.
Protocol Amendment No.: 07
Date: 13-Nov-2020 47
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
6.2 Exclusion Criteria
1) Target Disease Exceptions
a) Active brain metastases or leptomeningeal m etastases. Participants with brain metastases 
are eligible if these have been  treated and there is no magneti c resonance imaging (MRI 
except where contraindicated in which CT scan is acceptable) evidence of progression for 
at least 8 weeks after treatment is complete and within 28 days  prior to first dose of study 
drug administration. Cases should be discussed with the medical monitor. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day 
prednisone equivalents) for at least 2 weeks prior to study dru g administration.
b) Resectable oligometastastic only disease with multidisciplina ry plan for complete resection 
of all disease.
c) Ascites that cannot be controlled with medical therapy alone.
2) Medical Conditions
a) Participants with an active, known or suspected autoimmune di sease. Participants with type 
I diabetes mellitus, hypothyroidism only requiring hormone repl acement, skin disorders 
(such as vitiligo, psoriasis, or alopecia) not requiring system ic treatment, or conditions not 
expected to recur in the absence of an external trigger are perm itted to enroll.
b) Participants with a conditi on requiring systemic treatment wi th either corticosteroids 
(> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 
14 days of randomizatio n. Inhaled or topical steroids, and adren al replacement steroid 
doses > 10 mg daily prednisone equivalent, are permitted in the absence of active 
autoimmune disease.
c) Prior malignancy active within the previous 3 years except fo r locally curable cancers that 
have been apparently cured (ie, basal or squamous cell skin canc er, superficial bladder 
cancer, or carcinoma in sit u of the pros tate, cervix, or breast) and considered to be of low 
risk of recurrence
d) History of interstitial lung disease or pneumonitis.
e) Clinically significant cardiovascular disease. Pre-existing h ypertension should be 
adequately controlled to < 140/90 mmHg.
f) Clinically significant bleeding diathesis or coagulopathy.g) Deep venous thrombosis, pulmonary embolism, arterial thrombos is or cerebrovascular 
accident within 6 months prior to enrollment.
h) Non-healing wound, ulcer, or bone fracture.
i) Participants with > Grade 1 peripheral neuropathy.j) Prior history of gastrointestinal perforation or abscess.
k) History of hemoptysis of ≥half teaspoon (2.5 mL) of red blood within 3 months pri or to
enrollment.
l) Any serious or uncontrolled medical disorder that, in the opi nion of the investigator, may 
increase the risk associated with study participation or st udy drug administrati on, impair 
the ability of the participant to receive protocol therapy, or interfere with the interpretation 
of study results.
Protocol Amendment No.: 07
Date: 13-Nov-2020 48
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
m) Any other sound medical, psychiatr ic and/or social reason as determined by the 
investigator.
3) Prior/Concomitant Therapy
a) Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or  anti-CTLA-4 antibody, or 
any other antibody or dr ug specifically targeting T-cell co-stimulation or checkpoint 
pathways.
b) Received cancer-r elated investigational product(s) (IPs) and/ or biologic therapy within 
28 days or 5 half-lives, whichev er is longer, prior to rando mization.
c) Prior major surgery, open biopsy or significant traumatic inj ury within 28 days prior to 
randomization. Any w ound-related AE(s) must have resolved at least 28 days prior to  
randomization.
d) Prior focal palliative radiotherapy must have been completed at least 14 days prior to 
randomization.
e) Treatment with botanical preparations (eg herbal supplements or traditional Chinese 
medicines) intended for gener al health support or to treat the disease under study within 2 
weeks prior to randomization/tr eatment, except with the approva l of the Principal 
Investigator. Refer to Section 7.7.1 for prohibited therapies.
f) Participants who have received a live / attenuated vaccine wi thin 30 days of first treatment.
4) Physical and Laboratory Test Findings
a) WBC < 2000/μL
b) Neutrophils < 1500/μLc) Platelet s < 100×10
3/μL
d) Hemoglobin < 9.0 g/dLe) PT/INR and PTT > 1.5 ×ULN
f) Serum creatinine > 1.5 ×ULN, unless creatinine clearance ≥40 mL/min (measured or 
calculated using the Cockroft-Gault formula)
g) AST/ALT: > 3.0 ×ULN, unless participant has documented liver metastases in which case 
AST/ALT > 5.0× ULN are exclusionary.
h) Total bilirubin > 1.5 ×ULN (except participants with Gilbert Syndrome who must have a 
total bilirubin level of < 3.0 ×ULN)
i) Albumin < 3.0 g/dL
j) For participants with proteinur ia ≥2+ by urine dipstick or ur inalysis at baseline, 24-hr urine 
must be collected.  Proteinuria > 1g/24hrs is exclusionary. It i s acceptable to estimate urine 
protein to creatinine rati o (UPCR) instea d of 24hr urine collec tion. UPCR > 1000 mg/g is 
exclusionary.
k) Any positive test result for hepatitis B virus or hepatitis C  virus indicating presence of 
virus, eg, Hepatitis B surface antigen (HBsAg, Australia antigen ) positive, or Hepatitis C 
antibody (anti-HCV) positive (e xcept if HCV-RNA negative).
l) Known history of positive test for human immunodeficiency vir us (HIV) or known 
acquired immunodeficiency syndrome (AIDS). NOTE: Testing for HI V must be performed 
at sites where mandated locally. See Appendix 10.
Protocol Amendment No.: 07
Date: 13-Nov-2020 49
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
5) Allergies and Adverse Drug Reaction
a) Any contraindications to a ny of the st udy drugs of the chemotherapy regimen. Investigators 
should refer to local package insert of the SOC chemotherapy dr ugs and bevacizumab.
b) History of severe hypersensitivity reaction to any monoclonal  antibody.
c) History of allergy or hypersensitivity to study  drug components
6) Other Exclusion Criteria
a) Prisoners or participants who are involuntarily incarcerated.  (Note: under specific 
circumstances a person who has been imprisoned may be included as a participant. Strict 
conditions apply and Bristol-Myers Squibb approval is required.
b) Participants who are compulsorily detained for treatment of either a psychiatric or physical 
(eg, infectious disease) illness
Eligibility criteria for this study have been carefully conside red to ensure the safety of the study 
participants and that the results of the study can be used. It is imperative that participants fully 
meet all eligibility criteria.
6.3 Lifestyle Restrictions
Not applicable. No restrictions are required. Please also refer t o local SOC products labels for 
possible restrictions.
6.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but who 
are not subsequently randomized in the study/included in the ana lysis population. A minimal set 
of screen failure information is required to ensure transparent  reporting of screen failure 
participants, to meet the Consolidated Sta ndards of Reporting T rials (CONSORT) publishing 
requirements, as applicable, and to respond to queries from regu latory authorities. Minimal 
information includes date of consent, demography, screen failur e details, eligibility criteria, and 
any serious AEs.
6.4.1 Retesting During Screening
Participant Re-enrollment: This study permits the re-enrollment  of a participant that has 
discontinued the study as a pre-t reatment failure  (ie, particip ant has not been randomized / has not 
been treated). If re-enrolled, the participant must be re-consen ted.
Retesting of laboratory parameters and/or other assessments wit hin any single Screening or Lead-
in period will be permitted (in addition to any parameters that  require a confirmatory value).
The most current result prior to Randomization is the value by which study inclusion will be 
assessed, as it represents the participant’s most current, clin ical state.
Laboratory parameters and/or assessments that are included in Table 2-1 , Screening Procedural 
Outline may be repeated in an effort to find all possible well-qu alified participants. Consultation 
with the Medical Monitor may be needed to identify whether repe at testing of any particular 
parameter is clinically relevant.
Protocol Amendment No.: 07
Date: 13-Nov-2020 50
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
7 TREATMENT
Study treatment is defined as any investigational treatment(s),  marketed product(s), placebo or 
medical device intended to be administered to a st udy participant acc ording to the st udy 
randomizatio n or treatment allocation
Study treatment includes both Inve stigational [Medicinal] Produc t (IP/IMP) and 
Non-investigational [Medicinal] Product (Non-IP/Non-IMP) and ca n consist of the following:
•Nivolumab
•Oxaliplatin
•Leucovorin 
•Fluorouracil 
•Bevacizumab 
An investigational product, als o known as investigational medic inal product in some regions, is 
defined a pharmaceutical form of an active substance or placebo  being tested or used as a reference 
in a clinical study, including products already with a marketin g authorization but used or 
assembled (formulated or packaged) differently than the authori zed form, or used for an 
unauthorized indication, or when used to gain further informati on about the authorized form.
Other medications used as support or escape medicati on for preventative,  diagnostic, or therapeutic 
reasons, as components of the standard of care for a given diag nosis, may be considered as non-
investigational products.
Protocol Amendment No.: 07
Date: 13-Nov-2020 51
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Table 7-1: Study treatments for CA2099X8
Product Description 
/ Class and Dosage 
FormPotency IP/Non-IMP Blinded or 
Open LabelPackaging / 
AppearanceStorage 
Conditions
(per label)
Nivolumab
(BMS-936558-01)
Solution for 
Injectiona100 mg (10 
mg/ml)  and 
40 mg (10
mg/mL)IP Open label Vial and various 
packaging 
configurations2°to 8°C. 
Protect from 
light and
freezing.
Oxaliplatinb various
strengthsIP Open label Vial and various
packaging 
configurationsRefer to the 
label on
container and/or
Pharmacy 
manual.
ቄLeucovorin
CalciumFolinateቅb various
strengthsIP Open label Vial and various
packaging 
configurationsRefer to the 
label on
container and/or
Pharmacy 
manual.
Fluorouracilb various
strengthsIP Open label Vial and various
packaging 
configurationsRefer to the 
label on
container and/or
Pharmacy 
manual.
Bevacizumabb various
strengthsIP Open label Vial and various
packaging 
configurationsRefer to the 
label on
container and/or
Pharmacy 
manual.
Further instructions with regard to the preparation, handling, and storage for above product will be provided to sites separately as Pharmacy manual.
aMay be labeled as either “ BMS-936558-01”  or “Nivolumab”
bThese products may be obtained by the investigational sites as local commercial products in certain countries if 
allowed by local regulations. In these cases, products may be in a different pack size/potency/pharmaceutical form than listed in the table. These products should be prepared/sto red/administered in accordance with the package 
inserts or summaries of product characteristics (SmPCs).
Protocol Amendment No.: 07
Date: 13-Nov-2020 52
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
7.1 Treatments Administered
The selection and timing of dose for each participant is as fol lows:
Table 7.1-1: Selection and Timing of Dose
Study Treatment Unit dose strength(s)/Dosage level(s) Dosage formulation
Frequency of 
AdministrationRoute of 
Administration
Oxaliplatin 85 mg/m2Q2W IV
Leucovorin 400 mg/m2or 350 mg/m2as per local 
standardsQ2W IV
Fluorouracil Bolus 400 mg/m2Q2W IV
Fluorouracil 1200 mg/m2
continuous infusion on Day #1 (or Day #15) 
and 1200 mg/m² continuous infusion on 
Day #2 (or Day #16)
OR
2400 mg/m2continuous infusion over 46 to 
48 hours Day #1 (or Day #15) through 
Day #2 (or Day #16) as per local standardsQ2W IV
Bevacizumab 5 mg/kg Q2W IV
Nivolumab 240 mg Q2W IV
IV, intravenous. 
When study drugs (nivolumab and SOC therapy) are to be administ ered on the same day, 
nivolumab is to be administered first. Nivolumab i nfusion must  be promptly followe d by a saline 
flush to clear the line of nivolumab before starting SOC therapy  infusion(s ). The second i nfusion 
will always be the standard of care and will start after the inf usion line has been flushed, filters 
changed and the patient has been observed to ensure no infusion  reaction has occ urred. The time 
between infusions is expected to be approximately 30 minutes bu t may be more or less depending 
on the situation.
Participants will be treated until progression, unacceptable toxi city, withdrawal of consent, or the 
end of the study, whichever comes first. Nivolumab will be give n for a maximum of 24 months.
Participants should receive nivolumab at a dose of 240 mg as a 30 minute infusion on Day 1 of 
each treatment cycle every 2 weeks ( ±3 days) for a maximum of 24 months, or until c onfirmed 
progression, unacceptable toxicity, withdrawal of consent, or t he study ends, whichever occurs 
first. Participants should begin study treatment within 3 calen dar days of randomization. 
There will be no dose escalations or reductions of nivolumab al lowed. Participants may be dosed 
no less than 12 days from the  previous dose during Q2W cy cles. Premedications are not 
recommended for the first dose of nivolumab.
Protocol Amendment No.: 07
Date: 13-Nov-2020 53
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Participants should be carefully monitored for infusion reactio ns during study drug administration. 
If an acute infusion reaction is noted, participants should be managed according to Section 7.4 .
Doses of nivolumab may be interrupted, delayed, or discontinued  depending on how well the 
participant tolerates the treatment. Dosing visits are not skip ped, only delayed. Resumption of 
treatment should be at the ne xt scheduled time point.
Nivolumab infusion must be promptly followed by a saline flush to clear the line. Instructions for 
dilution and infusion of nivolumab injection may be provided in the  clinical protocol , pharmacy 
binder, or pharmacy manual. Care must be taken to assure steril ity of the prepared solution as the 
product does not contain any antimicrobial preservative or bact eriostatic agent. 
Where applicable (ex. bevacizuma b), dosing calcula tions should be based on the body weight 
assessed at baseline. It is not necessary to recalculate subsequent doses if the participant weight is 
within 10% of the weight used to calculate the previous dose. A ll doses should be rounded up to 
the nearest milligram per institutional standard.
Nivolumab plus SOC and bevacizumab arm
Participants assigned to nivolumab plus SOC will receive nivoluma b 240 mg administered IV over 
30 minutes first, then followed by bevacizumab administration a nd finally by the FOLFOX 
administration.First administration (C1D1) of bevacizumab will be delivered over  a 90-min infusion. If well 
tolerated the second administration (C1D15) will be delivered ove r 60 min; if the 60-min infusion 
is well tolerated, all subsequent infusions will be delivered ov er 30 min or as per local institutional 
standards.
Bevacizumab administration will then be followed by oxaliplatin  85 mg/m
2, leucovorin 
400 mg/m2, and fluorouracil 400 mg/m2will be administered IV on Day 1 of each treatment cycle 
every 2 weeks, and fluorouracil 1200 mg/m2IV continuous i nfusion on Day 1 and on Day 2 or 
2400 mg/m² over 46 to 48 hours of each t reatment cycle every 2 weeks (see  Table 7.1-1 ). Dosing 
windows for subsequent mFOLFOX doses should adhere to recommend ations in the prescribing 
information or local sta ndards, where indicated.
Premedication may be administrated per local standard, but are not recommended for the first dose 
of nivolumab.
SOC and bevacizumab arm
Participants assigned to SOC w ill receive bev acizumab first, follo wed by FOLFOX administration.
First administration (C1D1) of bevacizumab will be delivered ove r a 90-min infusion. If well 
tolerated the second administration (C1D15) will delivered over 60 min; if the 60-min infusion is
well tolerated, all subsequent infusions will be d elivered over 30 min or as per local institutional 
standards.
Bevacizumab administration will then be followed by oxaliplatin 85 mg/m2, leucovorin 
400 mg/m2, and fluorouracil 400 mg/m2administered IV on Day 1 of each tr eatment cycle, and 
Protocol Amendment No.: 07
Date: 13-Nov-2020 54
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
fluorouracil 1200 mg/m2IV continuous infusion on Day 1 and on Day 2 or 2400 mg/m² over 46 to 
48 hours of each tr eatment cycle, every 2 weeks (see Table 7.1-1 ).Dosing windows for subsequent 
FOLFOX doses should adhere to reco mmendations in the prescribin g informati on or local 
standards, where indicated.
Premedication may be administrated per local standard.
7.2 Method of Treatment Assignment
CA2099X8 is a randomized, open-label study. After the participa nt’s initial eligibility is 
established and informed consent has been obtained, the partici pant must be enrolled into the study 
by using an Interactive Response Technology (IRT) to obtain the participant number. Every 
participant that signs the informed consent form must be assigne d a participant number using IRT. 
Specific instructions for using IRT will be provided to the investigational site in a separate 
document.
All participants will be centr ally randomized using an Interact ive Response Technology (IRT). 
Before the st udy is init iated, each site user w ill receive log in information and directions on how 
to access the IRT. The investigator or designee will register th e participant for enrollment by 
following the enrollment procedures established by BMS.The following information is required for enrollment:
•Date that informed consent was obtained
•Date of birth, where applicable by local regulations
•Gender at birth
Once enrolled i n IRT, enro lled par ticipants who ha ve met all eligibility criteria will be ready t o be 
randomized through IRT. The following information is required for participant randomization:•Participant number
•Date of birth, where applicable per local regulations
•Tumor sidedness (left, right, transverse or unknown)
•Prior oxaliplatin-based adjuva nt chemotherapy (yes or no)
•Confirmation that evaluable tumor tissue has been received at t he central lab.
Participants meeting all eligibility criteria w ill be randomized in a 2: 1 ratio to nivolumab + SOC 
or SOC arms stratified by tumor sidedness and prior oxaliplatin-based adjuvant chemotherapy. 
Study treatment will  be dispensed at the study visits as listed in Schedule of Activities ( Section 2 ). 
The exact procedures for using the IRT will be detailed in the IRT manual.
Protocol Amendment No.: 07
Date: 13-Nov-2020 55
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
7.4 Dosage Modification
There are no dose modifications allowed for nivolumab, except treatment delay. If adverse events 
are considered to be related to study treatment, every attempt must be made to attribute individual 
study treatment t o adverse event, if possible, or to the combin ation regimen.
•For adverse events that are deemed to be related to mFOLFOX6 + bevacizumab ONLY by the 
treating physician, dose modification criteria for SOC must be followed as described in 
Sections 7.4.2 and7.4.3 .
•For adverse events that are deemed to be related to nivolumab O NLY by the treating physician, 
dose modification criteria for nivolumab must be followed as de scribed in Section 7.4.1 and 
Appendix 5 .
•For adverse events that are possibly related to the combination  regimen 
(nivolumab + mFOLFOX6 + bevacizumab), the most conservative toxic ity management 
guidelines must be followed.
•If there is a delay in administration of study drug(s) due to t oxicity, treatment with the other 
study agent(s) should continue as scheduled.  Resumption of tre atment should be at the next 
scheduled time point.
7.4.1 Nivolumab Dose Delay
Nivolumab administration should be delayed for the following:
•Grade 2 non-skin, drug-related AE, with the exception of fatigu e
•Grade 2 drug-related creatinine, AST, ALT and/or Total Bilirubi n abnormalities
•Grade 3 skin, drug-related AE
•Grade 3 drug-related laboratory abnormality, with the following  exceptions: 
−Grade 3 lymphopenia or asymptomatic amylase or lipase does not require dose delay
−Grade ≥3 AST, ALT, Total Bilirubin will require dose discontinuation ( see Sectio n 8.1.1 )
•Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the investigator, warrants delaying the dose of study medicatio n.
Participants who require delay of nivolumab should be re-evaluat ed weekly or more frequently if 
clinically indicated and resume nivo lumab dosing when re-treatm ent criteria are met.  If there is a 
delay or modif ication in administration of study drug(s) due to toxicity, tre atment with the other 
study agent(s) should conti nue as scheduled. If clinically appr opriate, the investigator can delay 
all treatment components up to a max imum of 7 days to allow synchroni zed administration of all 
agents.
7.4.2 Dose Modification Criteria for Oxaliplatin-Plus-Fluoropyrimidine 
Treatment
Dose modifications of oxaliplatin, leucovorin and fluorouracil are permitted according to local 
standards or local package inserts.
Protocol Amendment No.: 07
Date: 13-Nov-2020 56
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
7.4.2.1 General Guidance for Dose Modification for Chemotherapy
•Treatment for the first cycle should only commence if all the i nclusion criteria are met and the
participant has been enrolled. For subsequent cycles, dose delay /modification is permitted per
local standard .
•Doses of any study drug omi tted for toxicity are not rep laced or restored; ins tead, the patient 
should resume the planned treatment cycles. Supportive care (fo r example, colony-stimulating 
factors [CSFs], blood and blood products, etc. can be administe red in accordance with the latest 
American Society of Clinical Oncology (ASCO) or other equivalen t guidelines.
•Dose modification, for non-serious and non-life-threatening tox icities like alopecia, altered 
taste or nail changes may not be required and the final decisio n is left to the discretion of the 
treating investigator.
•In situations where c oncomitant toxicities of varying severity exist, dose modification w ill be 
tailored for the toxicity with highest CTCAE grading.
•If there is a delay or modification in administration of study drug(s) due to toxicity, treatment 
with the other study agent(s) should continue as scheduled. If clinically  appropriate, the 
investigator can delay all tr eatment components up to a maximum of 7 days to allow 
synchronized administration of all agents. 
If toxicity r elated to any component of chemotherapy does not resolve in the same treatment cycle, 
the administration of that component can be delayed up to 6 wee ks. If the toxicity does not resolve 
within 6 weeks, that component will be discontinued unless it i s determined by the treating 
investigator that the patient might benefit from continuation o f the component.
7.4.3 Dose Modification Criteria for mFOLFOX6
Recommended dose modifications of FOLFOX are provided in Table 7.4.3-1 and Table 7.4.3-2 .  
Modifications may be made as per local standards.
Table 7.4.3-1: Recommended Dose Modifications of FOLFOX
Drug Starting DoseDose Modification
Dose Level - 1 Dose Level - 2
Oxaliplatin 85 mg/m270 mg/m250 mg/m2
5-FUBolus 5-FU: 400 mg/m2
Leucovorin: 400 mg/m2  Infusion 
5-FU: 2400 mg/m2/ continuous 
infusion over 46-48 hoursBolus 5-FU: 300 mg/m2
Leucovorin: 300 mg/m2  Infusion 
5-FU: 2000 mg/m2/ continuous 
infusion over 46-48 hoursBolus 5-FU: 200 mg/m2
Leucovorin: 200 mg/m2Infusion 
5-FU: 1600 mg/m2/ continuous 
infusion over 46-48 hours
5-FU: 5-fluorouracil.
Protocol Amendment No.: 07
Date: 13-Nov-2020 57
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Table 7.4.3-2: Dose Modifications of FOLFOX
Toxicity DefinitionDuring a course of 
therapyDose adjustment for next 
treatments
Neutropenia Grade 3 or greaterInterrupt until resolved to 
Grade 2Dose level -1
*If treatment delayed for 
4 consecutive weeks, discontinue all 
treatment
ThrombocytopeniaGrade 2Interrupt until resolved to 
Grade 1Dose level -1
*If Grade 2 persists > 7 days, 
oxaliplatin reduced by 2 dose levels 
when platelets improve to Grade 1 
Grade 3Interrupt until resolved to 
Grade 1Dose level -1
*If Grade 3 persists > 7 days, 
oxaliplatin reduced by 2 dose levels 
when platelets improve to Grade 1
Grade 4Interrupt until resolved to 
Grade 1Dose level -2
*If Grade 4 persists > 7 days, 
oxaliplatin reduced by 2 dose levels 
when platelets improve to Grade 1
Neurologic toxicityGrade 2 peripheral 
sensory neuropathyInterrupt until resolved to 
Grade 1 or management as 
per institutional standardOxaliplatin dose -1
Continue 5-FU and leucovorin
*If oxaliplatin delayed for 
neurologic toxicity for 4 
consecutive weeks, discontinue
oxaliplatin, continue 5-FU and 
leucovorin
Grade 3 or greater 
peripheral sensory 
neuropathyDiscontinue oxaliplatin Continue 5-FU and leucovorin
Gastrointestinal 
toxicitiesGrade 2 or greater 
diarrheaInterrupt until resolved to 
Grade 1Dose level -1
If dose delayed for diarrhea for 
4 consecutive weeks, discontinue all 
treatment
For toxicities not listed above, dose modifications are permitt ed per local standards. 
Participants may also discontinue oxaliplatin following multipl e cycles if, in the investigator’s 
judgment, cumulative toxicity is likely to increase over time.
7.4.4 Dose Modification Criteria for bevacizumab
Dose modifications or de lay for bevacizumab are allowed per inst itutional standards.  
Protocol Amendment No.: 07
Date: 13-Nov-2020 58
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Table 7.4.4-1: Recommended Guidelines for Management of Proteinu ria
Grade DescriptionManagement
Grade 11+ protein on urinalysis, or 
0.15 to 1g of protein in 
24hrs urine collection, or
150 to 1000 mg/g if UPCR 
is used to assess the 
proteinuriaContinue Bevacizumab
Grade 22+ or 3+, or
1 to 3.4g/24hrs, or
1000 to 3400 mg/gGive Bevacizumab and collect 
24 hour urine or test UPCR 
before the next cycleResume Bevacizumab only if 
<2g/24hours, or < 2000 mg/g
If not <2g/24h, or < 2000 mg/g
for 3 months, discontinue 
Bevacizumab
Grade 3Urinary protein 
≥3.5 g/24hrs, or
≥ 3500 mg/gDiscontinue Bevacizumab
UPCR, urine protein to creatinine ratio
7.4.5 Treatment of Infusion-Related Reactions 
If an infusion-related reaction should occur, it might manifest  with fever, chills, rigors, headache, 
rash, pruritus, arthralgias, hypotension, hypertension, bronchospasm, or other allergic-like 
reactions. All Grade 3 or 4 i nfusion reactions s hould be reported withi n 24 hours to the study 
Medical Monitor/designee and reported as an SAE if it meets the  criteria. Infusio n reactions should 
be graded according to NCI CT CAE (Version 4) guid elines.
Treatment recommendations are provided below and may be modifie d based on local treatment 
standards and guidelines, as appropriate:
For Grade 1 symptoms: (mild reaction; infusion inte rruption not ind icated; intervention not 
indicated):
•Remain at bedside and monitor participant until recovery from s ymptoms. The following 
prophylactic premedications are recommended for future infusions: diphenhydramine 50 mg 
(or equivalent) and/or acetaminophen/paracetamol 325 to 1000 mg  at least 30 minutes before 
additional nivolumab administrations.
For Grade 2 symptoms : (moderate reaction required therapy or i nfusion inte rruption but responds 
promptly to symptomatic treatment (eg, antihis tamines, non-steroidal anti-inflammatory drugs, 
narcotics, corticosteroids, bronchodilators, IV fluids); prophylactic medications indicated for 
≤24 hours):
Protocol Amendment No.: 07
Date: 13-Nov-2020 59
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
•Stop the study treatment i nfusion, begin an IV infusion of normal saline, and tr eat the 
participant with diphenhydramine 50 mg IV (or equivalent) and/o r 
acetaminophen/paracetamol 325 to 1000 mg; remain at bedside and monitor participant until 
resolution of symptoms. Corticosteroid and/or bronchodilator th erapy may also be 
administered as appropriate. If the i nfusion is inte rrupted, then restart the i nfusion at 50% of 
the original infusion rate when symptoms resolve; if no further  complications ensue after 
30 minutes, the rate may be increased to 100% of the original in fusion rate. Monitor participant 
closely. If symptoms rec ur, then no further study treatment will be administered at tha t visit.
•For future infusions, the following prophylactic premedications are recommended: 
diphenhydramine 50 mg (or equivalen t) and/or acetaminophen/para cetamol 325 to 1000 mg 
should be administered at least 30 minutes before nivolumab inf usion. If necessary, 
corticosteroids (up to 25 m g of hydrocortisone or equiv alent) may be used.
For Grade 3 or 4 symptoms: (severe reaction, Grade 3: prol onged [ie, not rapidly responsiv e to 
symptomatic medication and/or brief interruption of infusion]; recurrence of symptoms following 
initial improv ement; hospi talization ind icated for other clinical sequelae (eg, renal impairment, 
pulmonary infiltrates). Grade 4:  Life-threatening; pressor or ve ntilatory support indicated):
•Immediately discontinue infusion of  study treatment. Begin an I V infusion of normal saline 
and treat the participant as follows: Recommend bronchodilators , epinephrine 0.2 to 1 mg of a 
1:1000 solution for subcutane ous administrati on or 0.1 to 0.25 mg of a 1:10,000 solution 
injected slowly for IV administration, and/or diphenhydramine 5 0 mg IV with 
methylprednisolone 100 mg IV (or equivalent), as needed. Participant should be monitored 
until the investigator is comfortable that the symptoms will no t recur. Study treatment will be 
permanently discontinued. Investigators should follow their ins titutional guidelines for the 
treatment of anaphylaxis. Remain at bedside and monitor partici pant until recovery of the 
symptoms.
In case of late-occurring hypersen sitivity symptoms (eg, appear ance of a localized or generalized 
pruritus within 1 week after treatment), symptomatic treatment may be given (eg, oral 
antihistamine or corticosteroids).
7.5 Preparation/Handling/Storage/Accountability
The investigational product should be stored in a secure area a ccording to local regulations. It is 
the responsibility of the investigator to ensure that investiga tional product is only dispensed to 
study Participants. The investigational product must be dispens ed only from official study sites by 
authorized personnel according to local regulations.
The product storage manager should ensure that the study treatm ent is stored in accordance with 
the environmental conditions (temperature, light, and humidity)  as determined by BMS. If 
concerns regarding the quality or appearance of the study treat ment arise, the study tr eatment
should not be dispensed a nd contact BMS immediately.
Protocol Amendment No.: 07
Date: 13-Nov-2020 60
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Study treatment not supplied by BMS will be stored in accordance  with the package insert.
Investigational product documentation (whether supplied by BMS or not) must be maintained that 
includes all processes required to ensure drug is accurately adm inistered. This includes 
documentation of drug storage, administration a nd, as applicable, storage temperatures, 
reconstitution, and use of required processes (eg, required dil uents, administration sets).
Further guidance and information for final disposition of unuse d study treatment are provided in 
Appendix 2 and Pharmacy Manual.  
7.6 Treatment Compliance
Study treatment complia nce will be periodi cally monitored by drug accountability. Drug 
accountability s hould be reviewed by the site study staff at each visit to confirm tr eatment 
compliance. 
7.7 Concomitant Therapy
7.7.1 Prohibited and/or Restricted Treatments
The following medications are prohibited during the study (unle ss utilized to treat a drug-related 
adverse event):
•Immunosuppressive agents
•Immunosuppressive doses of systemic corticosteroids (except as stated in Section 7.7.3 )
•Any concurrent anti-neoplastic therapy (ie, chemotherapy, hormo nal therapy, immunotherapy, 
extensive, non-p alliative rad iation therapy , or standa rd or investigational agents for treatment 
of CRC)
•Any botanical preparation (eg herbal supplements or traditional  Chinese medicines) intended 
to treat the disease unde r study or provide supportive care. Use of marijuana and its derivatives 
for treatment of symptoms related to cancer or cancer treatment  are permitted if obtained by 
medical prescription or if its use (even without a medical presc ription) has been legalized 
locally.
•Ongoing treatment with aspirin (>325 mg per day) or other medic ations known to predispose 
participants to gastrointestinal ulceration is prohibited for participants receiving bevacizumab.
•Also refer to local institutional guidelines and/or product lab els of SOC components for 
possible prohibited and/or restricted treatments.
•Any live / attenuated vaccine (e g varicella, zoster, yellow fev er, rotavirus, oral polio and 
measles, mumps, rubella [MMR]) during treatment and until 100 d ays post last dose.
7.7.2 Other Restrictions and Precautions
Participants with a condition requiring systemic treatment with  either corticosteroids (> 10 mg 
daily prednisone equivalent) or other immunosuppressive medicat ions within 14 days of 
Protocol Amendment No.: 07
Date: 13-Nov-2020 61
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
randomization are excluded. Inhaled or topical steroids, and ad renal replacement steroid doses 
> 10 mg daily prednisone equivalent, are permitted in the absenc e of active autoimmune disease.
7.7.3 Permitted Therapy
Participants are permitted the use of topical, ocular, intra-ar ticular, intranasal, and inhalational 
corticosteroids (with  minimal systemic absorpti on). Adrenal rep lacement steroid doses > 10 mg 
daily prednisone are permitted. A brief (less than 3 weeks) cou rse of corticosteroids for 
prophylaxis (e g, contrast dye allergy) or for tr eatment of non-auto immune conditions (e g, delayed-
type hypersensitivi ty reaction cau sed by a contact allergen) is permitted.
7.7.3.1 Imaging Restriction and PrecautionsIt is the local imaging facility’ s responsibility to determine,  based on participant attributes (eg, 
allergy history, diabetic history and renal status), the appropriate imaging mo dality and contrast 
regimen for each participant. Imaging contraindications and con trast risks should be considered in 
this assessment. Participants  with renal insufficiency s hould be a ssessed as to whether or not they 
should receive contrast and if so, what type and dose of contra st is appropriate. Specific to MRI, 
participants with severe renal insufficiency (ie, estimated glo merular filtration rate (eGFR) 
< 30 mL/min/1.73 m
2) are at increased risk of nephrogenic systemic fibrosis. MRI contrast should 
not be given to this participant population. In addition, participants are excluded from MRI if they 
have tattoos, metallic implants, pacemakers, etc.
The ultimate decision t o perform MRI in an individual participant in this study rests with the site 
radiologist, the investigator and the standard set by the local Ethics Committee.7.8 Post-Study Drug Access
At the conclusion of the study, participants who continue to de monstrate clinical benefit will be 
eligible to receive BMS supplied study treatment for the maximum treatment duration 
specified in protocol Section 7.1.Study treatment will be provided via an extension of the study,  
a rollover study requiring approval  by responsible health aut hority a nd ethics co mmittee or through 
another mechanism at the discretion of BMS.
BMS reserves the right to terminate access to BMS supplied stud y treatment if any of the following 
occur: a) the study is terminated due to safety concerns; b) the development of the nivolumab is 
terminated for other reasons, including but not l imited to lack of efficacy and/or not meeting the 
study objectives; c) the participant can obtain medication from a government sponsored or private 
healt h program. In all cases BMS will follow local regulations.
8 DISCONTINUATION CRITERIA
8.1 Discontinuation from Study Treatment
Participants MUST discontinue  investigational product (and non- investigational product at the 
discretion of the investigator) for a ny of the following reasons:
•Participant’s request to stop study tr eatment. Par ticipants who request to discontinue study 
treatment w ill remain in the study and must continue to be followed for pr otocol specified 
follow-up procedures. The only exception to this is when a part icipant specifically withdraws 
Protocol Amendment No.: 07
Date: 13-Nov-2020 62
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
consent for any further contact with him/her or persons previou sly authorized by participant to 
provide this information
•Any clinical adverse event (AE), laboratory abnormality or intercurrent illness which, in the 
opinion of the investigator, indicates that continued participation in the study is not in the best 
interest of the participant
•Termination of the study by Bristol-Myers Squibb (BMS)
•Loss of ability to fr eely provide consent through imprisonment or involuntarily inca rceration 
for treatment of either a psychiatric or physical (eg, infectious disease) illness
•Documented radiographic disease progression per RECIST v1.1.
•Criteria listed Section 8.1.1 and 8.1.2
Refer to the Schedule of Activities (see  Section 2)  for data to be collected at the time of treatment 
discontinuation and follow-up and for any further evaluations t hat can be completed.
In the case of pregnancy, the investigator must immediately not ify the Sponsor or designee of this 
event and study treatment must immediately be stopped. In most cases, the study drug will be 
permanently discontinued in an appropriate manner (eg, dose tap ering if necessary  for participant 
safety). Please contact the Sponsor or designee within 24 hours  of awareness of the pregnancy . If 
the investigator determines a possible favorable benefit/risk r atio that warrants continuation of 
study drug (ie, allowing restart of study treatment if particip ant chose to terminate the pregnancy), 
a discussion between the investigator and the Sponsor or design ee must occur so permission may 
be granted.
All participants who disc ontinue study treatment s hould comply with protocol specified follow-up 
procedures as outlined in Section 2 . The only exception to this requirement is when a participant
withdraws consent for all study  procedures including post-treat ment study follow-up or loses the 
ability to consent fr eely (ie, is imprisoned or involuntarily i ncarcerated for the treatment of either 
a psychiatric or physical illness).
If study treatment is discontinued prior to the participant’s co mpletion of the study, the reason for 
the discontinuation must be documented in the participant’s med ical records and en tered on the 
appropriate case report form (CRF) page.
8.1.1 Nivolumab Dose Discontinuation
Nivolumab treatment should be permanently discontinued for the following:
•Any Grade 2 drug-related uveitis, e ye pain or blurred vision th at does not respond to topical 
therapy and does not improve to Grade 1 severity within the re- treatment period OR requires 
systemic treatment
Protocol Amendment No.: 07
Date: 13-Nov-2020 63
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
•Any Grade 3 non-skin, drug-related AE lasting > 7 days or recur s, with the following 
exceptions for laboratory abnormalities, drug-related uveitis, pneumonitis, bronchospasm,
neurologic toxicity, hypersensitivity reactions, infusion react ions, and endocrinopathies:
−Grade 3 drug-related uveitis, pneumonitis, bronchospasm, neurol ogic toxicity, 
myocarditis, hypersensitivity reaction, or infusion reaction of  any duration requires 
discontinuation
−Grade 3 drug-related endocrinopathies, adequately controlled wi th only physiologic 
hormone replacement do not require d iscontinuation. Adrenal ins ufficiency requires 
discontinuation regardless of  control with hormone replacement.  
−Grade 3 drug-related laboratory a bnormalities do not require treatment discontinuation 
except:
♦Grade 3 drug-related thrombocytopen ia > 7 days or associated wi th bleeding requires 
discontinuation
♦Grade ≥3 drug-related AST, ALT or Total B ilirubin requires discontinua tion*
♦Concurrent AST or ALT > 3 ×ULN and total bilirubin > 2 ×ULN
* In most cases of Grade 3 AST or ALT elevation, study tr eatment w ill be permanently 
discontinued. If the investigator determines a possible favorab le benefit/risk ratio that warrants 
continuation of study treatment, a discussion between the inves tigator and the BMS Medical 
Monitor/designee must occur.
•Any Grade 4 drug-related adverse event or laboratory abnormalit y (including but not limited 
to creatinine, AST, ALT, or Total Bilirubin), except for the fo llowing events which do not 
require discontinuation:
−Grade 4 neutropenia ≤7 days
−Grade 4 lymphopenia or leukopenia or asymptomatic amylase or li pase
−Isolated Grade 4 electroly te imbalances/abnormalities that are not associated with clinical 
sequelae and are corrected with supplementation/appropriate management within 72 hours 
of their onset
−Grade 4 drug-related endocrinopathy adverse events, such as, hy per- or hypothyroidism, 
or glucose intolerance, which resolve or are adequately control led with physiologic 
hormone rep lacement (corticosteroids, thyroid hormones) or gluc ose-controlling agents, 
respectively, may not require discontinuation afte r discussion with an d approval from the 
BMS Medical Monitor.
•Any event that leads to delay in dosing lasting > 6 weeks from t he previous dose requires 
discontinuation, with the following exceptions:
−Dosing delays to allow for prolonged steroid tapers to manage d rug-related adverse events 
are allowed. 
−Dosing delays lasting > 6 weeks from the previous dose that occ ur for non-drug-related 
reasons may be allowed if approved by the BMS Medical Monitor (or designee). 
Protocol Amendment No.: 07
Date: 13-Nov-2020 64
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Prior to re-initiating treatment in a participant with a dosing  delay lasting > 6 weeks, the BMS 
Medical Monitor (or designee) must be cons ulted. Tumor assessme nts should continue as per 
protocol even if dosing is delayed. Periodic study visits to as sess safety and laboratory studies 
should also continue every 6 weeks or more frequently if clinically indicat ed during such dosing 
delays.
Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of the 
Investigator, presents a substantial clinical risk to the parti cipant with continued nivolumab dosing
8.1.2 SOC Dose Discontinuation
Except where specified below, the medications in the SOC chemothera py regimen should be 
discontinued for any of the following:
•Any Grade ≥4 drug-related peripheral neuropathy requires discontinuation o f oxaliplatin.
•In case of persistent Grade 3 drug-related paraesthesia, oxalipl atin should be discontinued.
•Any Grade ≥3 drug-related mucocutaneous reaction possibly attributable to l eucovorin 
requires permanent discontinuation.
•Grade ≥3 drug-related thrombocytopenia associated with clinically significant bleeding, all 
treatment s hould be held until resolved to ≤Grade 1. Subsequent dose reduction of any SOC 
medications or discontinuation of oxaliplatin will be at the di scretion of the treating 
investigator.
•Any drug-related liver function test (LFT) abnormality that mee ts the following criteria
requires discontinuation:
−AST or ALT > 5-10 ×ULN for > 2 weeks
−AST or ALT > 10 ×ULN
−Total bilirubin > 5 ×ULN
−Concurrent AST or ALT > 3 ×ULN and total bilirubin > 2 ×ULN
•Any oxaliplatin-related decrease in  creatinine clearance to < 3 0 mL/min (us ing the Cockroft 
Gault formula) requires discontinuation of oxaliplatin.
•Any drug-related AE which recurs after 2 prior dose reductions for the same drug-related AE 
requires discontinuation of the drug(s) which was/were previously dose reduced.
•Any Grade ≥3 drug-related hypersensi tivity reaction or i nfusion r eaction requires 
discontinuation of the drug(s) felt to be causing the reaction.  The drug not felt to be related to 
the hypersensitivity r eaction or infusion reaction may be continued.
•Any Grade 4 drug-related AE which the investigator deems is ina ppropriate to be managed by 
dose reduction(s) requires discontinuation of the drug(s) felt to be causing the event. The drug 
not felt to be related to the event may be continued.
•If any drug-related toxicity does not resolve within 42 days, th at component will be 
discontinued unless it is determined by the treating investigat or that the participant might 
benefit from continuation of the component.
•In case of unexplained drug-related respiratory symptoms such as  non-productive cough, 
dyspnea, crackles, or radiological pulmonary infiltrates, oxali platin s hould be discontinued 
until further pulmonary investigation excludes interstitial lun g disease or pulmonary fibrosis.
Protocol Amendment No.: 07
Date: 13-Nov-2020 65
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Treatment with bevacizumab must be permanently discontinued according to the updated 
bevacizumab package insert including the following: 
•Grade 4 drug-related hypertension including hypertensive enceph alopathy
•Grade 3-4 drug-related hemorrhage 
•Grade 4 drug-related non-pu lmonary or non-CNS hemorrhage
•Grade ≥1 drug-related pulmona ry or CNS hemorrhage
•Drug-related arterial thromboembolic event (any grade)
•Any grade of drug-related congestive heart failure
•Grade 3 drug-r elated proteinuria
•Participants who develop drug-related gastrointestinal perforati on, tracheoesophageal fistula 
or any Grade 4 fistula.  Discontinue in patients with fistula fo rmation involving any internal 
organ 
•Participants who develop a drug-related severe ATE
•Grade 4 drug-related VTE, including pulmonary embolism
•Drug-related wound dehiscence (a ny grade –requiri ng medical or s urgical therapy)
•Drug-related reversible posterior leukoencephalopathy (any grade ,- confirmed by MRI)
•Other unspecified bevacizumab related AE’s (Grade 4)
For toxicities not listed above, the treating investigators can  decide to discontinue any individual 
chemotherapy agent or all chemotherapy agents if it is not the best interest in the participant per 
the local standards.
Post-treatment study follow-up is critically important and is e ssential to preserving participant 
safety and the integrity of the study. Participants who disconti nue study treatment will continue to 
be followed for collection of tumor surveillance assessments, s afety,  
 as per protocol.
8.1.3 Criteria to Resume Treatment with Nivolumab
Participants may resume treatment with study treatment when the  drug-related AE(s) resolve to 
Grade ≤1 or baseline value, with the following exceptions:
•Participants may resume treatm ent in the presence of Grade 2 fa tigue
•Participants who have not experienced a Grade 3 drug-related sk in AE may resume treatment 
in the presence of Grade 2 skin toxicity
•For participants with Grade 2 AST, ALT and/or Total Bilirubin a bnormalities, dosing may 
resume when laboratory values return to baseline and management  with corticosteroids, if 
needed, is complete.
•Drug-related pulmonary toxicity, diarrhea or colitis must have r esolved to baseline before 
treatment is resumed. Participants  with persistent Grade 1 pneu monitis after completion of a 
steroid taper over at least 1 month may be eligible for retreat ment if discussed with and 
approved by BMS Medical Monitor (or designee).
Protocol Amendment No.: 07
Date: 13-Nov-2020 66
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
•Participants with drug-related endocrinopathies adequately cont rolled with only physiologic 
hormone rep lacement may resume treatment after consultation with the BMS Medical Monitor 
(or designee). Adrenal insufficiency requires discontinuation r egardless of control with 
hormone replacement.
•Resumption of treatment should be at the next scheduled time po int.
8.1.4 Post Study Treatment Study Follow-up
In this study, overall survival is a key endpoint of the study. Post study follow-up is of critical 
importance and is essential to preserving participant safety an d the integrity of the study. 
Participants who discontinue study treatment must continue to b e followed for collection of 
outcome and/or survival follow-up data as required and in line with Section 5 until death or the 
conclusion of the study.
BMS may request that survival data be collected on all treated/ randomized particip ants outside of 
the protocol defined window (see Section 2 , Schedule of Activities table). At the time of this 
request, each participant will be contacted to determine their survival status unless the participant
has withdrawn consent for all contacts or is lost to follow-up8.2 Discontinuation from the Study
Participants who request to discontinue study treatment will rem ain in the study and must continue 
to be followed for protocol sp ecified follow-up procedures. The  only exception to this is when a 
participant specifically withdraws consent for any further cont act with him/her or persons 
previously authorized by participant to provide this information . 
•Participants should notify the investigator of the decision to withdraw consent from future 
follow-up in writing, whenever possible.
•The withdrawal of consent should be explained in detail in the medical rec ords by the 
investigator, as to whether the withdrawal is from further treatment with study treatment only 
or also from study proce dures and/or post treatment study follow-up, and entered on the  
appropriate CRF page.
•In the event that vital status (whether the participant is alive or dead) is being measured, publicly available information s hould be used to determine vital status only as appropriately 
directed in accordance with local law.
•If the participant withdraws consent for disclosure of future i nformation, the sponsor may 
retain and continue to use any data collected before such a wit hdrawal of consent.
8.3 Lost to Follow-Up
•All reasonable efforts must be made to locate participants to d etermine and report their ongoing 
status. This include s follow-up with pers ons authorized by the participant.
•Lost to follow-up is defined by the inability to reach the part icipant after a minimum of three
documented phone calls, faxe s, or emails as well as lack of response by participant to one 
registered mail letter. All attempts should be documented in th e participant’s medical records.
Protocol Amendment No.: 07
Date: 13-Nov-2020 67
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
•If it is determined that the participant has died, the site will  use permissible local methods to 
obtain date and cause of death.
•If investigator’s use of third-party representative to assist i n the follow- up portion of the study 
has been included in the participant’s informed consent, then t he investigator may use a 
Sponsor retained third-party representative to assist site staf f with obtaining participant’s 
contact information or other public vital s tatus data n ecessary to complete the follow-up 
portion of the study. 
•The site staff and representative will consult publicly availab le sources, such as public h ealth 
registries and databases, in order to obtain updated contact in formation.
•If after all attempts, the participant remains lost to follow-u p, then the last known alive date as 
determined by the investigator should be reported and documente d in the participant’s medical 
records.
9 STUDY ASSESSMENTS AND PROCEDURES
•Study procedures and timing are summarized in the Schedule of A ctivities (see  Section 2) . 
•Protocol waivers or exemptions are not allowed.
•All immediate safety concerns must be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
treatment.
•Adherence to the study design requirements, including those spe cified in the Schedule of 
Activities (see  Section 2) , is essential and required for study conduct.
•All screening evaluations must be completed and reviewed to con firm that potential 
participants meet all eligibility criteria before randomization . The investigator will maintain a 
screening log to record details of all participants screened an d to confirm eligibility  or rec ord 
reasons for screening failure, as applicable.
•Procedures conducted as part of  the participant’s routine clini cal management (eg, blood count) 
and obtained before signing of  informed consent may be utilized  for screening or baseline 
purposes provided the procedure meets the protocol-defined criteria and has been performed 
within the timeframe defined in the Schedule of Activities (see  Section 2) .
Additional measures, including non-study required laboratory te sts, should be performed as 
clinically ind icated or to comply with local regu lations. Laboratory toxicities (eg, suspected drug 
induced liver enzyme evaluations) will be monitored during the follow-up phase via on-site/local 
labs until all study drug-related toxicities resolve, return to  baseline, or are deemed irreversible.
If a participant shows pulmona ry-related signs (hypoxia, fever)  or symptoms (eg. dyspnea, cough, 
fever) consistent with possible pulmonary adverse events, the p articipant should be immediately 
evaluated to rule out pulmonary toxicity, according to the susp ected pulmonary toxicity 
management algorithm in the BMS-936558 (nivolumab) Investigator  Brochure.
Some of the assessments referred to in this section may not be captured as data in the eCRF. They 
are intended to be used as safety monitoring by the treating ph ysician. Additional testing or 
Protocol Amendment No.: 07
Date: 13-Nov-2020 68
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
assessments may be performed as clinically necessary  or where required by institutional or lo cal 
regulations.
9.1 Efficacy Assessments
9.1.1 Imaging Assessment for the Study
Images will be submitted to an imaging core lab. Sites should be  trained prior to scanning the first 
study participant. Image acquisiti on guidelines and submission process will be ou tlined in the 
CA2099X8 Imaging Manual to be provided by the core lab. 
Baseline imaging, including CT of the chest, CT/MRI of the abdom en, pelvis, and all known sites 
of disease should be performed within 28 days prior to first dose. 
At Baseline, MRI of the brain without and with contrast is requ ired for participants with known or 
suspected brain metastases. Part icipants with a history of brai n metastasis should have surveillance 
MRI approxima tely every 12 week s, or sooner if clinically indic ated
First tumor assessment post-baseline should be pe rformed at Week 12 ( ±7 days) after 
randomization and then every 8 weeks ( ±7 days) thereafter until confirmed progression, 
withdrawal of consent, or the study ends, whichever occurs first . If the investigator finds
progression that is not confirmed by BICR, additional CT of the chest, CT/MRI of the abdomen, 
pelvis, and all known sites of disease should be performed 4 weeks later, prior to subsequent 
therapy.
Bone scan, PET scan or plain films  are not considered adequate imaging techniques to measure 
bone lesions. However, these techniques can be used to confirm the presence or disappearance of 
bone lesions. Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue 
components that can be evaluated by cross sectional imaging tec hniques such as CT or MRI can 
be considered as measurable lesions  if the soft tissue componen t meets the definition of 
measurability described above.
Any additional imaging that may demonstrate tumor response or p rogression (including scans 
performed at unscheduled timepoints and/or at an outside instit ution) should be co llected for 
RECIST v1.1 tumor assessment and submitted to the BICR.
Assessments of PR and CR must be confirmed at least 4 weeks afte r initial res ponse. A Best 
Response of SD can only be made after the participant is on-stu dy for a minimum of 42 days from 
the date of randomizat ion. Investigators w ill also re port the number and size of new lesions that 
appear while on study. The time point of tum or assessments w ill be re ported on the eCRF based 
on the investigator’s assessment. 
9.1.1.1 Methods of Measurement
Tumor assessment with contrast-enhanced computed tomography (CT ) scans acquired on 
dedicated CT equipment is preferred for this study. Contrast-en hanced CT of the chest, abdomen, 
pelvis, and other known/suspected sites of disease should be pe rformed for tumor assessments. 
Protocol Amendment No.: 07
Date: 13-Nov-2020 69
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Should a participant have contraindication for CT intravenous c ontrast, a non-contrast CT of the 
chest and a contrast-enhanced MRI of the abdomen, pelvis, and o ther known/suspected sites of 
disease should be obtained.   
Should a par ticipant have contraindication for both MRI and CT intravenous c ontrasts, a non-
contrast CT of the chest and a non-contrast MRI of the abdomen,  pelvis, and other 
known/suspected sites of disease should be obtained. 
Should a participant have contraindication for MRI (eg, incompa tible pacemaker) in addition to 
contraindication to CT intravenous contrast, a non-contrast CT of the chest, abdomen, pelvis, and 
other known/suspected sites of disease is acceptable.CT and MRI scans should be acquired with s lice thickness of 5 mm or less with no intervening 
gap (contiguous). Every attempt should be made to image each participant using an identical 
acquisition protocol on the s ame scanner for all imaging time po ints. 
Use of CT component of a PET-CT scanner: Combined modality scan ning such as with FDG PET-
CT is increasingly used in clinical care, and is a modality/tec hnology that is in rapid evolution; 
therefore, the recommendations outlined here may change rather quickly with time. At present, 
low dose or attenuation correction CT portions of a combined FDG PET-CT are of limited use in 
anatomically-based efficacy assessments and it is therefore sug gested that they should not be 
substituted for dedi cated diagnostic contra st enhanced CT scans  for anatomically-based RECIST 
measurements. However, if a site can document that the CT perfo rmed as part of a FDG PET-CT 
is of identical diagnostic quality to a diagnostic CT (with IV and oral contrast) then the CT portion 
of the FDG PET-CT can be used for RECIST 1.1 measurements. Note , however, that the FDG 
PET portion of the CT introduces additional data which may bias  an investigator if it is not 
routinely or serially performed.
Participants with a history of bone metastasis may have a bone scan, if clinically indicated.
9.1.1.2 BICR Assessment of Progression
Sites should submit all scans to a BICR, preferably within 7 da ys of scan acquisition, throughout 
the duration of the study. BICR will review scans, and remain bl inded to treatment arm and 
investigator assessment of submitted scans. When progression per RECIST 1.1 criteria is assessed 
by the investigator, the site will inform the imaging core lab,  so that the BICR assessment of 
progression can be expedited in a manner that does not unnecess arily alert the BICR team to the 
investigator's assessment. The BICR review will be completed and  limited results provided to the 
site.
Participants whose progression is not confirmed by the BICR sho uld perform an additional CT of 
the chest, CT/MRI of the abdomen, pelvis, and all known sites of  disease 4 weeks after initial 
progression, prior to subsequent therapy. Also, if participants  discontinue treatment without 
radiographic progression, tumor asse ssments will c ontinue accor ding to the protocol-specified 
schedule, as noted in until progression has been confirmed by BICR.All study treatment decisions will be based on the investigator ’s assessment of tumor images and 
not on the BICR assessment. The BICR assessment of progression is only relevant for determining 
Protocol Amendment No.: 07
Date: 13-Nov-2020 70
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
when tumor assessments for a given participant are no longer re quired to be submitted to the 
imaging vendor.
 
9.2 Adverse Events
The definitions of an AE or serious adverse event (SAE) can be found in Appendix 3 .
Immune-mediated adverse events are AEs consistent with an immun e-mediated mechanism or 
immune-mediated component for which non-inflammatory etiologies  (eg, infection or tumor 
progression) have been ruled out. IMAEs can include events with  an alternate etiology which were 
Protocol Amendment No.: 07
Date: 13-Nov-2020 71
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
exacerbated by the induction of autoimmunity. I nformation suppo rting the assessment will be 
collected on the participant’s case report form.
AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally a uthorized repre sentative). 
The investigator and any designees are responsible for detectin g, documenting, and reporting 
events that meet the definition of an AE or SAE and remain resp onsible for following up AEs that 
are serious, considered related to the study treatment or the s tudy, or that caused the participant to 
discontinue before completing the study. 
Contacts for SAE reporting specified in Appendix 3
9.2.1 Time Period and Frequency for Collecting AE and SAE Information
The collection o f nonserious AE i nformation should begin at initiation of study treatment until the 
time points specified in the Schedule of Activities ( Section 2 ). Nonserious AE information should 
also be collected from the start of a placebo lead-in period or  other observational period intended 
to establish a baseline status for the participants.
Sections 5.6.1 a nd 5.6.2 in the Investigator Brochure (IB) repre sent the Reference Safety 
Information to determine expectedness of serious adverse events  for expedited reporting. 
Following the participant’s written consent to par ticipate in the study, all SAEs, whether related 
or not related to stud y drug, must be co llected, including thos e thought to be associated with 
protocol-specified procedures.
All SAEs must be collected that occur during the screening peri od and within 100 days of the last 
dose of study treatment. For participants randomized/assigned t o treatment and never treated with 
study drug, SAEs should be co llected for 30 days  from the  date of randomization.
The investigator must report any SAE that occurs after these ti me periods and that is believed to 
be related to study drug or protocol-specified procedure.
•Medical occurrences that begin before the start of study treatment but after obtaining informed 
consent will be recorded on the appropriate section of the eCRF module.
•All SAEs will be rec orded and reported to Sponsor or designee within 24 hours, as indicated 
in Appendix 3 . 
•The investigator will submit any updated SAE data to the sponso r or designee within 24 hours 
of this updated information being available.
Investigators are not obligated  to actively seek AEs or SAEs in  former study participants. 
However, if the investigator learns of any SAE, including a dea th, at any time after a participant 
has been discharged from the study, and he/she considers the event reasonably related to the study 
treatment or study participatio n, the investigator must promptl y notify the sponsor.
The method of evaluating, and assessing caus ality of AEs and SAEs and the procedures for 
completing and reporting/transmitting SAE reports are provided in Appendix 3.
Protocol Amendment No.: 07
Date: 13-Nov-2020 72
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
9.2.2 Method of Detecting AEs and SAEs
Adverse events can be spontaneously reported  or elicited  during open-ended questioning, 
examination, or evaluation of a participant. Care should be tak en not to introduce bias when 
collecting AE and/or SAEs.  I nquiry a bout sp ecific AEs s hould be gui ded by clinical judgement 
in the context of known adverse events, when appropriate for the program or protocol.
9.2.3 Follow-up of AEs and SAEs
•Nonserious AEs should be follo wed to resolution  or stabilizatio n, or reported as SAEs if they 
become serious (see Section Appendix 3 ).
•Follow-up is also required for nonserious AEs that cause interr uption or discontinuation of 
study treatment and for those present at the end of study treat ment as appropriate.
•All identified nonserious AEs must be recorded and described on  the nonserious AE page of 
the CRF (paper or electronic). Completion of supplemental CRFs may be requested for AEs 
and/or laboratory abnormalities t hat are reported/identified du ring the course of the study.
After the initial AE/SAE report, the investigator is required t o proactively follow each participant 
at subsequent visits/contacts. All SAEs, and non-serious AEs of  special interest (as defined in 
Section 9 will be followed until resolution, until the condition stabiliz es, until the event is 
otherwise explained, or until the participant is lost to follow -up (as defined in Section 8.3 ).
Further informatio n on follow- up procedures is given in Appendix 3 .
9.2.4 Regulatory Reporting Requirements for SAEs•Prompt notification by the investigator to the Sponsor of SAEs is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a 
product under clinical investigation are met.
•An investigator who receives an i nvestigator safety report desc ribing SAEs or other specific 
safety information (eg, summary  or listing of SAEs) from the S ponsor w ill file it along with 
the Investigator’s Brochure and w ill notify the IRB/IEC, if appropri ate acc ording to local 
requirements.
Sponsor or designee w ill be reporting adverse events to regu latory authorities and ethics 
committees according to local applicable laws including Europea n Directive 2001/20/EC and FDA 
Code of Federal Regulations 21 CFR Parts 312 and 320. A SUSAR ( Suspected, Unexpected 
Serious Adverse Reaction) is a subset of SAEs and will be repor ted to the appropriate regulatory 
authorities and investigators following local and global  guidelines  and requirements.
9.2.5 Pregnancy
If, following initiation of the study treatment, it is subseque ntly discovered that a participant is 
pregnant or may have been pregnant at the time of study exposur e, including during at least 
5 half-lives after product administr ation, the investigator must immediately notify the BMS 
Medical Monitor/designee of this event and complete and forward  a Pregnancy Surveillance Form 
Protocol Amendment No.: 07
Date: 13-Nov-2020 73
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
to BMS Designee within 24 hours of awareness of the event and in accordance with SAE reporting 
procedures described in Appendix 3 .
If the investigator determines a possible favorable benefit/ris k ratio that warrants continuation of 
study treatment, or re-initiation of study treatment, a discuss ion between the investigator and the 
BMS Medical Monitor/designee must occur. If, for whatever reaso n, the pregnancy has ended, 
confirmed by negative serum pregnancy test, treatment may be re sumed (at least 3 weeks and not 
greater than 6 weeks after the pregnancy has ended), following approvals of participant /sponsor 
/IRB/EC, as applicable.
In most cases, the study treatment will be permanently discontin ued in an appropriate manner (eg,
dose tapering if necessary for participant safety). Please call the BMS Medical Monitor within 24 
hours of awareness of the pregnancy.
Follow-up information regarding the course of the pregnancy, in cluding perinatal and neon atal 
outcome and, where applicable, offspring information must be re ported on the Pregnancy 
Surveillance Form.
Any pregnancy that occurs in a female partner of a male study participant should be reported to 
Sponsor or designee. In order for Sponsor or designee to collec t any pregnancy surveillance 
information from the female partne r, the fe male pa rtner must si gn an informed consent form for 
disclosure of this information. Information on this pregnancy w ill be collected on the Pregnancy 
Surveillance Form.
9.2.6 Laboratory Test Result Abnormalities
The following laboratory test result abnormalities should be ca ptured on the nonserious AE CRF 
page or SAE Report Form electronic, as appropriate. Paper forms are only intended as a back-up 
option when the electronic system is not functioning.
•Any laboratory test result that is clinically significant or me ets the definition of an SAE 
•Any laboratory test result abnormality that required the partic ipant to have study treatment
discontinued or interrupted
•Any laboratory test result abnormality that required the participant to receive specific 
corrective therapy
It is expected that wherever possible, the clinical rather than laboratory term would be used by the 
reporting investigator (eg, anemia versus low hemoglobin value) .
9.2.7 Potential Drug Induced Liver Injury (DILI)
Wherever possible, t imely confirmation of initial liver-related  laboratory abnormalities s hould 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meeting 
the defined criteria, must be reported as SAEs (see Appendix 3  for reporting details).
Potential drug induced liver injury is defined as: 
1) AT (ALT or AST) elevation > 3 ×ULN
Protocol Amendment No.: 07
Date: 13-Nov-2020 74
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
AND
2) Total bilirubin > 2 ×ULN, without initial findings of cholest asis (elevated serum alkaline 
phosphatase),
AND3) No other immediately apparent possible causes of AT elevation  and hyperbilirubinemia, 
including, but not limi ted to, viral hepatitis, pre-existing ch ronic or acute liver disease, or the 
administration of other drug(s) known to be hepatotoxic.
For participants with elevated AST or ALT or Total bilirubin at baseline, potential DILI is defined 
as: 
1) AT (ALT or AST) elevation > 2× baseline AND 3× ULN; OR
AT elevation 8 times ULN
AND
2) Total bilirubin > 2× baseline AND >2× ULN, without initial f indings of cholestasis 
(elevated serum alkaline phosphatase),
AND
3) No other immediately apparent possible causes of AT elevatio n and hyperbilirubinemia, 
including, but not limited to, viral hepatitis, pre-existing ch ronic or acute liver disease, or the 
administration of other drug(s) known to be hepatotoxic.
9.2.8 Other Safety Considerations
Any significant worsening noted during interim or final physica l examinations, electrocardiogram, 
x-ray filming, any other potential safety assessment required o r not required by protocol should 
also be recorded as a nonserious or serious AE, as appropriate, and reported accordingly.
9.3 Overdose
An overdose is defined as the accidental or intentional adminis tration of any dose of a product that 
is considered both excessive  and medically important. Overdoses  that meet the regulatory 
definition of SAE will be reported as an SAE (see  Appendix 3 ). 
9.4 Safety
Planned time points for all safety  assessments are listed in th e Schedule of Activities (see 
Section 2 ).
9.4.1 Physical Examinations
Refer to Schedule of Activities (see Section 2) .
9.4.2 Vital signs
Refer to Schedule of Activities (see Section 2).
Protocol Amendment No.: 07
Date: 13-Nov-2020 75
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
9.4.3 Clinical Safety Laboratory Assessments
Investigators must document their review of each laboratory saf ety report.
Hematology - CBC
Hemoglobin
Hematocrit
Total leukocyte count, including differential
Platelet count
Chemistry
Aspartate aminotransferase (AST)
Alanine aminotransferase (ALT)
Total bilirubin
Alkaline phosphatase (ALP)Lactate dehydrogenase (LDH)
Creatinine
Blood Urea Nitrogen (BUN) or serum UREAGlucose (fasting or not)
PT/INR – screening and as clinically 
indicated during bevacizumab treatmentPTT - screeningAlbumin - screening onlySodium
Potassium
ChlorideCalcium
Phosphorus
TSH, free T3 and free T4 - screening TSH, with reflexive fT3 and fT4 if TSH is 
abnormal - on treatment 
Urinalysis
Urinalysis or urine dipstick including protein, glucose, blood,  leukocyte esterase, specific 
gravity, pH. 24hr urine collection or UPCR required if a protein urine dipstick reading is ≥2+.
Serology
Hepatitis B/C, (HBV sAG, HCV antibody or HCV RNA), - screening o nly. If anti-HCV test is 
positive, then HCV RNA is mandatory.
Other Analyses
CEA (and CA19-9) Assessment
Pregnancy test (WOCBP only: minimum sensitivity 25 IU/L or equi valent units of HCG).
Follicle s timulating hormone (FSH) screening -only required to confirm me nopause in women 
< age 55) 
9.4.4 Imaging Safety Assessment
Any incidental findings of potential clinical relevance that ar e not directly associated with the 
objectives of the protocol should be evaluated and handled by t he Study Investigator as per 
standard medical/clinical judgment. 
Protocol Amendment No.: 07
Date: 13-Nov-2020 76
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 77
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
 
Protocol Amendment No.: 07
Date: 13-Nov-2020 78
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 79
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 80
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
 
Protocol Amendment No.: 07
Date: 13-Nov-2020 81
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
10.2 Populations for Analyses
For purposes of analysis, the following populations are defined :
Population Description
Enrolled All participants who signed an informed consent form a nd were registered 
into the IRT system
Randomized All participants who were randomized to any treatment  arm in the study.
This is the primary population for analyses of efficacy.
Treated (Safety) All participants w ho received at least one dose  of study treatment 
(nivolumab or SOC).
10.3 Statistical AnalysesThe statistical analysis plan will be developed and finalized before database lock and will describe 
the selection of participants to be included in the analyses, a nd procedures for accounting for
missing, unused, and spurious data. Below is a su mmary of planned statistical analyses of the 
primary and secondary endpoints. A description of the participan t population will be included in 
the statistical output reported, including subgroup of age, gen der, and race.
10.3.1 Efficacy Analyses
Endpoint Statistical Analysis Methods
Primary Progression-free survival (PFS) is defined as the time f rom rando mizatio n date
to the date of the first docum ented tumor progression, as determined by BICR
(per RECIST v1.1), or death due to any cause, whichever occurs first. 
•Participants who die without a reported prior progression and wi thout 
initiation of subsequent anti-cancer therapy will be considered to have 
progressed on the date of their death. 
•Participants who did not progress or die will be censored on th e date of their 
last evaluable tumor assessment. 
•Participants who did not have any on study tumor assessments and did not 
die will be censored on the randomization date.
Protocol Amendment No.: 07
Date: 13-Nov-2020 82
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Endpoint Statistical Analysis Methods
•Participants who started any subsequent anti-cancer therapy with out a prior 
reported progression or prior to death w ill be censored at the last tumor 
assessment prior to initiation of the subsequent anti-cancer th erapy.
Further explanation for various censoring scenarios for PFS will  be specified in 
SAP.
The distribution of PFS will be c ompared in the two randomized arms via a 
two-sided, log-rank test stratified by randomization stratifica tion factors of 
tumor sidedness and prior oxaliplatin-based adjuvant chemothera py at the 
overall significance level of .20 (two-sided).
The hazard ratio (HR) and the corresponding 95% confidence inte rval (CI) will 
be estimated in a stratified Cox proportional hazar ds model using the 
randomized arm as a single covariate, stratified by tumor sided ness and prior 
oxaliplatin-based adjuvant chemotherapy.
The PFS curves for each randomized arm will be estimated using the Kaplan-
Meier (KM) product limit method. Med ian PFS and the corresponding  two-
sided 95% CIs using the log-lo g transformation will be computed.  In addition, 
PFS rates at a specified time point (e.g., 12, 24 months), and the corresponding 
two-sided 95% CIs using the log-log transformation, will be comput ed.
Secondary Objective Response Rate (ORR) is defined as the number  and percentage of 
participants with a best overall response (BOR) of confirmed co mplete 
response (CR) or partial response (PR). Best overall response ( BOR) is defined 
as the best response designation, recorded between the date of randomization
and the date of the initial ob jectively documented tumor progression per 
RECIST v1.1 or the date of subsequent therapy, whichever occurs  first. For 
participants without documented progression or subsequent thera py, all 
available response designations will contribute to the BOR deter mination.
Disease Control Rate (DCR) is defined as the proportion of participants whose BOR is CR or PR or SD among all randomized participants.
Time to Response (TTR) is defined as the time from the date of randomization 
to the date of first confirmed CR or PR. TTR will be evaluated f or responders 
only.Duration of objective res ponse (DoR) is defined as the time between the date 
of first confirmed response to the date of the first documented  tumor 
progression (per RECIST 1.1), or death due to any cause, whiche ver occurs 
first. The rules of censoring are the same as PFS. DoR w ill be evaluated for 
responders (ie, participants with confirmed CR or PR) only.
Protocol Amendment No.: 07
Date: 13-Nov-2020 83
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Endpoint Statistical Analysis Methods
The endpoints above will be asse ssed by both BICR and investiga tor where 
applicable.
OS is defined as the time from the date of rando mization to the d ate of death. 
A participant who has not died will be censored at last known date alive.The ORR will be summarized by binomial response rates and their  
corresponding two-sided 95% exact CIs are calculated using the C lopper-
Pearson method.OS curves will be estimated using KM product-limit methodology.  Median OS 
with two-sided 95% CIs using the log-log transformation will be  computed. In 
addition, OS rates at a specif ic time point (e.g., 12, 24 months ) with two-sided 
95% CIs using the log-log transformation, will be computed.Other secondary variables including TTR, DoR, and DCR will be su mmarized 
in the following ways. Time to event variables will be analyzed in a similar 
way as OS. Binary variables will be summarized in a similar way as ORR.
Quantitative variables will be summarized using the mean, median, minimum 
and maximum values, and standard deviation. Categorical variabl es will be 
summarized using tables presenting counts and percentages for e ach category. 
10.3.2 Safety Analyses
Endpoint Statistical Analysis Methods
Secondary The safety analysis w ill be performed in all parti cipants who have received at 
least 1 dose of study  treatment. Des criptive statistics of safe ty will be presented 
using CTCAE (Version 4) by treatmen t arm. Adverse events, treatme nt-related 
AEs, SAEs and treatment-r elated SAEs will be tabulated using worst grade per 
CTCAE (Version 4) by system organ class and preferred term. On-study 
clinical laboratory a bnormalities will be summarized using worst  grade per 
CTCAE (Version 4).
10.3.4 Interim Analyses 
O
ne interim analysis (IA) is planned in the Phase 2 portion of th e study  
. The decisio n flow is described in Section 5.1.
Protocol Amendment No.: 07
Date: 13-Nov-2020 84
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
The Statis
tical An alysis Plan will further describe the planned interim an alysis.
Protocol Amendment No.: 07
Date: 13-Nov-2020 85
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 86
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 87
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 88
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 89
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Protocol Amendment No.: 07
Date: 13-Nov-2020 90
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 91
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 92
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 93
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 94
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
12 APPENDICES
Protocol Amendment No.: 07
Date: 13-Nov-2020 95
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
APPENDIX 1 ABBREVIATIONS AND TRADEMARKS
Term Definition
5-FU 5-Fluorouracil
AE adverse event
ALT alanine aminotransferase
AST aspartate aminotransferase
BICR blinded independent central review
BMS Bristol-Myers Squibb
BOR best overall response
BP blood pressure
BUN blood urea nitrogen
CBC complete blood count
CEA Carcinoembryonic Antigen
CFR Code of Federal Regulations
CI confidence interval
CNS Central nervous system
CR complete response
CRC colorectal cancer
CRF Case Report Form, paper or electronic
CTAg Clinical Trial Agreement
DCR disease control rate
dL deciliter
DOR Duration of  response
ECG electrocardiogram
ECOG eastern cooperative oncol ogy group
eCRF Electronic Case Report Form
EDC Electronic Data Capture
eg exempli gratia (for example)
Protocol Amendment No.: 07
Date: 13-Nov-2020 96
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Term Definition
FDA Food and Drug Administration
FFPE formalin-fixed paraffin embeded
FSH follicle stimulating hormone
gG ram
GCP Good Clinical Practice
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCG human chorionic gonadotrophin
HCV hepatitis C virus
HIV Human Immunodeficiency Virus
HR heart rate
ICH International Conference on Harmonisation
ie id est (that is)
IEC Independent Ethics Committee
IHC immunohistochemistry
IMP investigational medicinal products
IND Investigational New Drug Exemption
I-O Immuno-oncology
IP/IMP investigational product/investigational medicinal product
IRB Institutional Review Board
IRT interactive response technology
IU International Unit
IV intravenous
kg kilogram
L Liter
LDH lactate dehydrogenase
LFT Liver function tests
Protocol Amendment No.: 07
Date: 13-Nov-2020 97
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Term Definition
mCRC metastatic colorectal cancer
mg milligram
mg microgram
min minute
mL milliliter
mmHg millimeters of mercury
MMR mismatch repair (of DNA)
mOS median overall survival
MRI magnetic resonance imagining 
MSI microsatellite instability
MSI-H microsatellite instability high
MSS microsatellite stability
N/A not applicable
NCCN national comprehensive cancer network
ORR objective response rate
OS overall survival
PD-L1 program cell death ligand 1
PFS progression-free survival
Protocol Amendment No.: 07
Date: 13-Nov-2020 98
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Term Definition
PR partial response
SAE serious adverse event
SAP statist ical analysis plan
SD stable disease
SOP Standard Operating Procedures
TSH Thyroid stimulating hormone
TTR time to response
ULN Upper limit of normal
US united states
WBC white blood cell
WOCBP women of childbearing potential
Protocol Amendment No.: 07
Date: 13-Nov-2020 99
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
APPENDIX 2 STUDY GOVERNANCE CONSIDERATIONS
The term ‘Participant’ is us ed in the protocol to refer to a person who has consented to participate 
in the clinical research study.  The term ‘Subject’ used in the  eCRF is intended to refer to a person 
(Participant) who has consented to participate in the clinical research study.
REGULATORY AND ETHICAL CONSIDERATIONS
GOOD CLINICAL PRACTICE
This study will be conducted in accordance with:
•Good Clinical Practice (GCP), 
•consensus ethical principles derived from international guidelines including the Declaration of 
Helsinki and Council for International Organizations of Medical  Sciences (CIOMS) 
International Ethical Guidelines Good Clinical Practice (GCP)
•as define d by the Internati onal Council on Harmonisation (ICH)
•in accordance with the ethical principles underlying European U nion Directive 2001/20/EC
•United States Code of Federal Regulations, Title 21, Part 50 (2 1CFR50) 
•applicable local requirements.
The study will be condu cted in compliance with the protocol. The protocol and any amendments 
and the participant informed consent will r eceive approval/favorable opinion by Institutional 
Review Board/Independent Ethics Committee (IRB/IEC), and regulatory authorities according to 
applicable local regulations prior to initiation of the study.
All potential serious breaches must be reported to Sponsor or d esignee immediately. A breach of 
the conditions and principles of Good Clin ical Pr actice (GCP) (occ urring in any c ountry) in 
connection with that trial or the protocol related to the trial which is likely to affect to a significant 
degree the safety or physical  or mental integrity  of 1 or more subjects of the trial or the scientific 
value of the trial. 
Personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks.This study will not use the services of study personnel where s anctions have been invoked or where 
there has been scientific misconduct or fraud (eg, loss of medi cal licensure, debarment). 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE
Before study initiation, the investigator must have written and  dated approval/favorable opinion 
from the IRB/IEC for the protocol, consent form, participant re cruitment materials (eg, 
advertisements), and any other written information to be provid ed to subjects. The  investigator or 
BMS should als o provide the IRB/IEC with a copy of the  Investigator Brochure or product labeling 
information to be provided to subjects and any updates. 
Protocol Amendment No.: 07
Date: 13-Nov-2020 100
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
The investigator, Sponsor or designee should provide the IRB/IE C with reports, updates and other 
information (eg, expedited safety reports, amendments, and admi nistrative letters) according to 
regulatory requirements or institution procedures.
COMPLIANCE WITH THE PROTOCOL AND PROTOCOL REVISIONS
The investigator should not implement any dev iation or change to the protocol without prior 
review and documented approval/favorable opinion of an amendmen t from the IRB/IEC (and if 
applicable, also by local health authority) except where necessa ry to eliminate an immediate 
hazard(s) to study participants. 
If a deviation or change to a protocol is implemented to elimin ate an immediate hazard(s) prior to 
obtaining relevant  approval/favorable opinion(s) the deviation  or change will be submitted, as 
soon as possible to:
•IRB/IEC
•Regulatory Authority(ies), if applicable by local regulations ( per national requirements)
Documentation of approval/favorable opinion signed by the chair person or designee of the 
IRB(s)/IEC(s) and if applicable, also by local health authority  must be sent to BMS.
If an amendment substantially alters the study design or increa ses the potential risk to the 
participant: (1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review 
and approval/favorable opinion; (2) the revised form must be us ed to obtain consent from 
participants currently enrolled in the study if they are affected by the amendment; and (3) the new form must be used to obtain cons ent from new participan ts prior  to enrollment.
If the revision is done via an administrative letter, investiga tors must inform their IRB(s)/IEC(s).
FINANCIAL DISCLOSURE
Investigators and su b-Investigators will provide the Sponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the Sponsor to submit comp lete and 
accurate financial certification or disclosure statements to th e appropriate h ealth aut horities. 
Investigators are responsible fo r providing information on financial interests during the course of 
the study and for 1 year after completion of the study.
INFORMED CONSENT PROCESS
Investigators must ensure that participants are clearly and ful ly informed about the purpose, 
potential risks, and other critical issues regarding clinical s tudies in which they volunteer to 
participate. 
In situations where consent cannot be given to participants, th eir legally acceptable representatives 
(as per country guidelines) are clearly and fully informed abou t the purpose, potential risks, and 
other critical issues regarding clinical studies in which the p articipant volunteers to participate. 
Sponsor or designee will provide the investigator with an appro priate (ie, Global or Local) sample
informed consent form which will include all elements required by ICH, GCP and applicable
Protocol Amendment No.: 07
Date: 13-Nov-2020 101
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
regulatory requirements. The sample informed consent form will a dhere to the ethical principles 
that have their origin in the Declaration of Helsinki.
Investigators must:
•Provide a copy of the consent form and written information about the study in the language in 
which the participant is most proficient prior to clinical study participation. The language must 
be non-technical and easily understood. 
•Allow time necessary for participant or participant's legally a cceptable representative to 
inquire about the details of the study.
•Obtain an informed consent signed and personally dated by the p articipant or the participant's 
legally acceptable representative and by the person who conduct ed the informed consent 
discussion. 
•Obtain the IRB/IEC’s written approval/favorable opinion of the written informed consent form 
and any other information to be provided to the participants, prior to the beginning of the study, 
and after any revisions are completed for new information.
If informed consent is initially given by a participant’s legal ly acceptable representative or legal 
guardian, and the participant subsequently becomes capable of m aking and communicating his or 
her informed consent during the study, consent must additionally be obtained from the participant.
Revise the informed consent whenever important new information becomes available that is 
relevant to the participant's consent. The investigator, or a p erson designated by the investigator, 
should fully inform the participant or the participant's legall y acceptable representative or legal 
guardian, of all pertinent aspects of the study and of any new information relevant to the 
participant's willingness to continue participation in the stud y. This commun ication should be 
documented. 
The confidentiality of records that could identify participants  must be protected, respecting the 
privacy and confidentiality rules applicable to regulatory requ irements, the participants' signed 
ICF and, in the US, the participants’ signed HIPAA Authorizatio n.
The consent form must also include a statement that BMS and reg ulatory authorities have direct 
access to participant records. Participants unable to give their written consent (e.g., stroke  or participants with or severe 
dementia) may only be enrolled in the study with the consent of  a legally acceptable representative. 
The participant must also be informed about the nature of the s tudy to the extent compatible with 
his or her understanding, and should this participant become ca pable, he or she should personally 
sign and date the consent form as soon as possible. The explici t wish of a participant who is unable 
to give his or her written consent, but who is capable of formi ng an opinion and assessing 
information to refuse participation in, or to be wit hdrawn from, the clin ical study at a ny time should 
be considered by the investigator.The rights, safety, and well-being of the study participants ar e the most important considerations 
and should prevail over interests of science and society.
Protocol Amendment No.: 07
Date: 13-Nov-2020 102
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
SOURCE DOCUMENTS
The Investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attr ibutable, whether the data are hand-written on paper or entered 
electronically. If source  data are created (first entered), mod ified, maintained, archived, retrieved, 
or transmitted electronically via computer ized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such s ystems must be compliant with all 
applicable laws and regulations governing use of electronic rec ords and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), 
adverse event tracking/reporting, protocol required assessments , and/or drug accountability 
records).
When paper records from such systems are used in place of electronic format to perform regulated 
activities, such paper records should be certified copies. A ce rtified copy consists of a copy of 
original information that has been verified, as indicated by a dated signature, as an exact copy 
having all of the same attributes a nd information as the original. 
STUDY TREATMENT RECORDS
Records for study treatments (w hether supplied by BMS, its vendors, or the site) must substantiate 
study treatment integrity and traceability from receipt, preparation, administration, and through 
destruction or return. Records must be made available for revie w at the request of BMS/designee 
or a Health Authority.
Protocol Amendment No.: 07
Date: 13-Nov-2020 103
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
If Then
Supplied by BMS (or its vendors): Records or logs must comply wi th applicable 
regulations and guidelines and should include:
•amount received and placed in storage 
area
•amount currently in storage area
•label identification number or b atch 
number
•amount dispensed to and returned by each 
participant, including unique participant 
identifiers
•amount transferred to another area/site for 
dispensing or storage
•nonstudy disposition (e.g., lost, wasted) 
•amount destroyed at study site, if 
applicable
•amount returned to BMS
•retain samples for 
bioavailability/bioequivalence, if 
applicable 
•dates and initials of person responsible for 
Investigational Product 
dispensing/accountability, as per the 
Delegation of Authority Form.
Sourced by site, and not supplied by BMS or 
its vendors (examples include IP sourced from the sites stock or commercial supply, or a specialty pharmacy)The investigator or designee accepts responsibilit y for documenting traceability and 
study treatment integri ty in accordance with 
requirements applicable under law and the SOPs/standards of the sourcing pharmacy. 
BMS or designee will provide  forms to facilitate inventory cont rol if the investigational site does not have an 
established system that meets these requirements.
CASE REPORT FORMS
An investigator is required to prepare and maintain adequate an d accurate case histories designed 
to record all observations and other d ata pertinent to the investig ation on each individual treated 
or entered as a control in the investigation. Data that are derived from source documents and 
reported on the CRF must be consistent with the source document s or the discrepancies must be 
explained. Additional clinical information may be collected and  analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
Protocol Amendment No.: 07
Date: 13-Nov-2020 104
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
For sites using the Sponsor or designee electronic data capture tool, electronic CRFs w ill be 
prepared for all data collection fields except for fields speci fic to SAEs and pregnancy, which will 
be reported on the electronic SAE form and Pregnancy Surveillan ce form, respectively. If 
electronic SAE form is not av ailable, a paper SAE form can be used. Spaces may be left blank  
only in those circumstances permitted by study-specific CRF com pletion guidelin es provi ded by 
Sponsor or designee.
The confidentiality of records that could identify participants  must be protected, respecting the 
privacy and confidentiality rules in accordance with the applic able regulatory requirement(s).
The investigator will maintain a signature sheet to document si gnatures and initials of all persons 
authorized to make entries and/or corrections on CRFs. The completed CRF, SAE/pregnancy CRFs, must be promptly reviewe d, signed, and dated by the 
investigator or qualified physician who is a subinvestigator and who is delegated this task on the 
Delegation of Authority Form. Subinvestigators in Japan may not  be delegated the CRF approval 
task.  For electronic CRFs, review and approval/signature is co mpleted electronically through the 
BMS electronic data capture tool.  The investigator must r etain a copy of the CRFs including 
records of the changes and corrections.
Each individual electronically si gning electronic CRFs must mee t Sponsor or designee training 
requirements and must only access the BMS electronic data captur e tool using the unique user 
account provided by Sponsor or designee. User accounts are not to be shared or reassigned to other 
individualsMONITORING
Sponsor or designee representativ es will review data centrally t o identify potential issues to 
determine a schedule of on-site visits for targeted review of s tudy records. 
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity . On site they will review stud y records and directly compare them 
with source documents, discuss the conduct of the study with th e investigator, and verify that the 
facilities remain acceptable .Certain CRF pages and/or electron ic files may serve as the source 
documents:
In addition, the study may be evaluated by Sponsor or designee in ternal auditors and government 
inspectors who must be allowed access to CRFs, source documents , other study files, and study 
facilities. BMS audit reports will be kept confidential.
The investigator must notify BMS promptly of a ny inspections scheduled by regulatory aut horities, 
and promptly forward copies of inspection reports to Sponsor or  designee.
RECORDS RETENTION
The investigator (or head of the study site in Japan) must reta in all study records and source 
documents for the maximum period required by applicable regulat ions and guidelines, or 
institution procedures, or for the period specified by BMS or d esignee, whichever is longer. The 
Protocol Amendment No.: 07
Date: 13-Nov-2020 105
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
investigator (or head of the study site in Japan) must contact B MS prior to destroying any records 
associated with the study.
BMS or designee will notify the investigator (or head of the st udy site in Japan) when the study 
records are no longer needed.If the investigator withdraws from the study (eg, relocation, r etirement), the records sh all be 
transferred to a mutually agreed upon designee (eg, another inve stigator, study site, IRB). Notice 
of such transfer will be given in writing to BMS or designee. 
RETURN OF STUDY TREATMENT
For this study, study treatments (those supplied by BMS, a vend or or sourced by the investigator) 
such as partially used study treatment containers, vials and sy ringes may be destroyed on site. 
If.. Then
Study treatments supplied by BMS (including 
its vendorsAny unused study treatments s upplied by BMS 
can only be destroyed after being inspected 
and reconciled by the responsible Study 
Monitor unless study treatments containers must be immediately destroyed as required for safety, or to meet local regulations (eg, 
cytotoxics or biologics).
If study treatments will be returned, the return 
will be arranged by th e responsible Study 
Monitor.
Study treatments sourced by site, not supplied by BMS (or its vendors) (examples include study treatments sourced from the sites stock 
or commercial supply, or a specialty 
pharmacy)It is the investigator’s or designee’s 
responsibility to dispose of all containers according to the institutional guidelines and procedures.
It is the investigator’s or designee’s responsibility to arrange for disposal, provided that procedures for proper disposal have been established according to applicab le federal, state, local, and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. The following minimal standards must be met:
•On-site disposal practices must not expose humans to risks from  the drug.
•On-site disposal practices and procedures are in agr eement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
•Written procedures for on-site disposal are available and follo wed. The procedures must be 
filed with the site’s SOPs and a copy  provided t o BMS upon request.
•Records are maintain ed that allow for traceability of each cont ainer, including the date
disposed of, quantity disposed, and identif ication of the person disposing the containers. The 
Protocol Amendment No.: 07
Date: 13-Nov-2020 106
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal vendor 
must be documented.
•Accountability and disposal rec ords are complete, up-to-date, a nd available for the Monitor to 
review throughout the clinical trial period.
It is the investigator’s or designee’s responsibility to arrange for disposal of all empty containers.
If conditions for destruction cannot be met the responsible Stu dy Monitor will make arrangements 
for return of study treatments provided by BMS (or its vendors) . Destruction of non- study 
treatments s ourced by the site, not supplied by BMS, is solely the responsibility of the investigator 
or designee.CLINICAL STUDY REPORT AND PUBLICATIONS
A Signatory Investigator must be selected to sign the clinical study report. 
For this protocol, the Signatory Investigator will be selected as appropriate based on the following 
criteria:
•National Coordinating Investigator
•Participant recruitment (eg, among the top quartile of enroller s)
•Regional representation (eg, amo ng top quar tile of enrollers from a sp ecified region or country)
•Other criteria (as determined by the study team)
The data collected during this study are confident ial and proprietary to Spons or or designee. Any 
publications or abstracts arising from this study must adhere to the publication requirements set 
forth in the clinical trial agreement (CTAg) governing [Study s ite or Investigator] participation in 
the study. These requirements include, but are not limited to, submitting proposed publications to 
Sponsor or designee at the earliest practicable time prior to s ubmission or presentation and 
otherwise within the time period set forth in the CTAg.
Protocol Amendment No.: 07
Date: 13-Nov-2020 107
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW UP AND REPORTING
ADVERSE EVENTS
Adverse Event Definition:
An Adverse Event (AE) is defined as any new untoward medical oc currence or worsening of a 
preexisting medical condition in a clinical investigation parti cipant administered study treatment 
and that does not necessarily hav e a causal relati onship with t his treatment. 
An AE can therefore be any unfavorable and unintended sign (suc h as an abnormal laboratory 
finding), symptom, or disease temporally associated with the us e of study treatment, whether or 
not considered related to the study treatment.
Events Meeting the AE Definition
•Any abnormal laboratory test results (hematol ogy, clinical chem istry, or urinalysis) or 
results from other safety assessments (eg, ECG, radiological sc a n s ,  v i t a l  s i g n s  
measurements), including those that worsen from baseline, considered clinically significant 
in the medical and scie ntific judgment of the investigator. Note  that abnormal lab tests or 
other safety assessments should only be reported as AEs if the final diagnosis is not 
available. Once the final diagnosis is known, the reported term  should be updated to be the 
diagnosis.
•Exacerbation of a chronic or in termittent pre-existing condition including either an increase 
in frequency and/or intensity of the condition.
•New conditions detected or diagnosed after study intervention a dministration even though it 
may have been present before the start of the study.
•Signs, symptoms, or the clinical sequelae of a suspected drug-d rug interaction.
•Signs, symptoms, or the clinical sequelae of a s uspected overdo se of either study intervention 
or a concomitant medication. Overdose, as a verbatim term (as r eported by the investigator), 
shoul d not be reported as an AE/SAE unless it is an intentional  overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported  regardless of sequelae and 
should specify "intentional overdose" as the verbatim term
Events NOT Meeting the AE Definition
•Medical or surgical proce dure (eg, endoscopy, appendectomy): th e condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occ urrence did not occur (so cial and/or 
convenience admission to a hospital).
DEFINITION OF SAE
If an event is not an AE per definition above, then it cannot b e an SAE even if serious conditions 
are met.
Protocol Amendment No.: 07
Date: 13-Nov-2020 108
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
SERIOUS ADVERSE EVENTS
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any 
dose:
Results in death
Is life-threatening (defined as an event in which the participant was at risk of deat h at the time 
of the event; it does not refer to an event which hypothetically might have caused death if it were 
more severe)
Requires inpatient hospitalization or causes prolongation of ex isting hospitalization (see NOTE 
below)
NOTE: 
The following hospitalizations are not  considered SAEs in BMS clinical studies: 
•a visit to the emergency room or other hospital department < 24 hours, that does not result 
in admission (unless considered an important medical or life-th reatening event)
•elective surgery, planned prior to signing consent
•admissions as per protocol for a planned medical/surgical procedure
•routine health assess ment requiring admission for baseline/tren ding of health status (e.g., 
routine colonoscopy)
•medical/surgical admission other  than to remedy ill health and planned prior to entry into 
the study. Appropriate documentation is required in these cases
•admission encountered for another life circumstance that carrie s no bearing on health status 
and requires no medical/surgical intervention (e.g., lack of housing, economic inadequacy, 
caregiver respite, family circumstances, administrative reason)
•admission for administr ation of anticancer therapy in the absence of any other SAEs (a pplies 
to oncology protocols)
Results in persistent or significant disability/incapacity
Is a congenital anomaly/birth defect
Is an important medical event (defined as a medical event(s) th at may not be immediately life-
threatening or result in death or hospitalization but, based up on appropriate medical and 
scientific judgment, may jeopardize the participant or may requ ire intervention [e.g., medical, 
surgical] to prevent one of the other serious outcomes listed i n the definition above.) Examples 
of such events include, but are not limited to, intensive treat ment in an emergency room or at 
home for allergic bronchospasm; blood dyscrasias or co nvulsions that do not result in 
hospitalization.) Potential drug indu ced liver injury (DILI) is also considered an important 
medical event. (See Section 9.2.7 for the definition of potential DILI.) 
Pregnancy and potential drug induced liver injury (DILI) must f ollow the same transmission timing 
and processes to BMS as used for SAEs (see section 9.2.5 for reporting pregnancies).
Protocol Amendment No.: 07
Date: 13-Nov-2020 109
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
EVALUATING AES AND SAES
Assessment of Causality
•The investigator is obligated to assess the relationship betwee n study intervention and each 
occurrence of each AE/SAE.
•A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relat ionship cannot be ruled out.
•The investigator will use clinical judgment to determine the re lationship.
•Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention administration will be considered and investigated.
•The investigator will also consult the Investigat or’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
•For each AE/SAE, the investigator must document in the medical notes that he/she has
reviewed the AE/SAE and has provided an assessment of causality .
•There may be situations in which an SAE has occurred and the in vestigator has minimal 
information to include in the initial report to Sponsor. Howeve r, it is very important that the 
investigator always make an assessment of causality for every e vent before the initial 
transmission of the SAE data to Sponsor.
•The investigator may change his/her opinion of causality in lig ht of follow-up information 
and send a SAE follow-up report with the updated causality asse ssment.
•The causality assessment is one  of the criteria used when deter mining regulatory reporting 
requirements.
Follow-up of AEs and SAEs
If only limited information is i nitially available, follow- up reports are required. (Note: Follow-
up SAE reports must include the same investigator term(s) initi ally reported.) 
If an ongoing SAE changes in its intensity or relationship to s tudy treatment or if new 
information becomes available, the SAE report must be updated and submitted within 24 hours 
to BMS (or designee) using the same procedure used for transmit ting the initial SAE report.
All SAEs must be followed to resolution or stabilization.
Protocol Amendment No.: 07
Date: 13-Nov-2020 110
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
REPORTING OF SAES TO SPONSOR OR DESIGNEE
•SAEs, whether related or not r elated to study treatment, and pregnancies must be reported 
to BMS (or designee) immediately within 24 hours of awareness of the event.
•SAEs must be recorded on the SAE Report Form.
−The required method for SAE data reporting is through the eCRF.
−The paper SAE Report Form is only intended as a back-up option when the electronic 
data capture (EDC) system is unavailable/not functioning for tr ansmission of the eCRF 
to BMS (or designee).
♦In this case, the paper form is transmitted via email or confir med facsimile (fax) 
transmission
♦When paper forms are used, the  original paper forms are to remain on site
•Pregnancies must be recorded on a paper Pregnancy Surveillance Form and transmitted via email or 
confirmed facsimile (fax) transmission 
SAE Email Address: Refer to Contact Information list.
SAE Facsimile Number: Refer to Contact Information list.
SAE Telephone Contact (required for SAE and pregnancy reporti ng): Refer to Contact 
Information list
Protocol Amendment No.: 07
Date: 13-Nov-2020 111
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
APPENDIX 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until beco ming post-menopausal unless 
permanently sterile. Permanent sterilization methods include hy sterectomy, bilateral 
salpingectomy , and bilater al oop horectomy.
Women in the following categories are not considered WOCBP
•Premenarchal
•Premenopausal female wi th 1 of the following:
−Documented hysterectomy
−Documented bilateral salpingectomy
−Documented bilateral oophorectomy
Note: Documentation can come from t he site personnel’s review of the participant’s medical 
records, medical examination, or m edical history interview.
•Postmenopausal female
−A postmenopausal state is defined as 12 months of ame norrhea in a woman over age 45 
years in the absence of other biological or physiological cause s. In addition, females under 
the age of 55 years must have a serum follicle stimulating hormone, (FSH) level > 40 
mIU/mL to confirm menopause.
CONTRACEPTION GUIDANCE FOR FEMALE PARTICIPANTS OF CHILD BEARING  
POTENTIAL
One of the highly effective methods of contraception listed belo w is required during study duration 
and until the end of relevant systemic exposure, defined as 6 mo nths after the end of study 
treatment. *
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of <1% per year when used consistently and correctly.a
•Combined (estrogen- and progestogen- containing) hormonal contraception associated with 
inhibition of ovulationb 
−oral 
−intravaginal 
−transdermal 
Protocol Amendment No.: 07
Date: 13-Nov-2020 112
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
•Progestogen -only hormonal contraception associated with inhibition of ovul ationb 
−oral 
−injectable 
Highly Effective Methods That Are User Independent
•Implantable progestogen-only hormonal contraception associated with inhibition of 
ovulationb
•Intrauterine hormone-releasing system (IUS)c
•Intrauterine device (IUD)c
•Bilateral tubal occlusion
•Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. 
If not, an additional highly effective method of contraception should be used. 
•Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the participant.
•It is not necessary to use any other method of contraception whe n complete abstinence is 
elected. 
•WOCBP participants who choose complete abstinence must continue to have pregnancy 
tests, as specified in Section 2. 
•Acceptable alternate methods of highly effective contraception must be discussed in the 
event that the WOCBP participants chooses to forego complete abs tinence 
NOTES: 
aTypical use failure rates may differ from those when used consi stently and correctly. Use should be consistent 
with local regulations regarding the use of contraceptive metho ds for participants participating in clinical studies. 
bHormonal contraception may be susceptible to interaction with t he study drug, which may reduce the efficacy 
of the contraceptive method.  Hormonal contraception is permissible only when there is sufficient evidence that 
the IMP and other study med ications will not alter hormonal exposures such that contracept ion would be 
ineffective or result in increased exposures that could be potentially hazardous.  In this case, alternative methods of contraception should be utilized. 
cIntrauterine devices and intrauterine hormone releasing systems are acceptable methods of contraception in the 
absence of definitive drug interaction studies when hormone exp osures from intrauterin e devices do not alter 
contraception effectiveness
Unacceptable Methods of Contraception*
•Male or female c ondom with or without spermicide.  Male and fem ale condoms cannot be 
used simultaneously
Protocol Amendment No.: 07
Date: 13-Nov-2020 113
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
•Diaphragm with spermicide
•Cervical cap with spermicide
•Vaginal Sponge with spermicide
•Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the 
primary mechanism of action
•Periodic abstinence (calendar, symptothermal , post-ovulation me thods)
•Withdrawal (coitus interruptus).
•Spermicide only
•Lactation amenorrhea method (LAM)
* Local laws and regulations may require use of alternative and/or additional contraception 
methods.
CONTRACEPTION GUIDANCE FOR MALE PARTICIPANTS WITH PARTNER(S) OF  
CHILD BEARING POTENTIAL.
Male participants with female partners of childbearing potentia l are eligible to participate if they 
agree to the following during the treatment and until the end of relevant systemic exposure.
•Inform any and all partne r(s) of their participation in a clini cal drug study and the need to 
comply with contraception instructions as directed by the inves tigator.
•Male participants are required to use a condom for study duration and until end of relevant 
systemic exposure defined as 7 months after the end of study tre atment.
•Female partners of males participating in the study to consider  use of effective methods of 
contraception until the end of relevant systemic exposure, defi ned as 7 months after the end of 
treatment in the male participant.
•Male participants with a pregnant or breastfeeding partner must agree to remain abstinent from 
penile vaginal intercourse or use a male condom during each epi sode of penile penetration 
during the treatment and until 7 months after the end of study tr eatment. 
•Refrain from donating sperm for the duration of the study treat ment and until 7 months after 
the end of study treatment.
COLLECTION OF PREGNANCY INFORMATION
Guidance for collection of Pregnanc y Information and outcome of  pregnancy on the Pregnancy 
Surveillance Form is provided in Section 9.2.5 and the Appendix for Adverse Events and Serious 
Adverse Events Definitions and procedures for Evaluating, Follo w-up and Reporting
Protocol Amendment No.: 07
Date: 13-Nov-2020 114
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
APPENDIX 5 NIVOLUMAB MANAGEMENT ALGORITHMS
These general guidelines constitute guidance to the Investigato r and may be supplemented by 
discussions with the Medical Monitor representing the Sponsor. The guidance applies to all 
immuno-oncology agents and regimens.
A general principle is that differential diagnoses should be di ligently evaluated according to 
standard medical practice. N on-inflammatory etiologies s hould be consider ed and appropriately 
treated.Corticosteroids are a primary t herapy for immuno-oncology drug- related adverse events. The oral 
equivalent of the recommended IV doses may be considered for am bulatory patients with low-
grade toxicity. The lower bioavailability of oral corticosteroi ds should be taken into account when 
switching to the equivalent dose of oral corticosteroids.Consultation with  a medical or s urgical specialist,  especially prior to an invasive diagnostic or 
therapeutic procedure, is recommended.The frequency and severity of the related adverse events covered by these algorithms will depend 
on the immuno-oncology agent or regimen being used.
Protocol Amendment No.: 07
Date: 13-Nov-2020 115
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 116
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 117
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 118
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 119
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 120
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 121
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 122
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 123
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
APPENDIX 6 ECOG PERFORMANCE STATUS 
These scales and criteria are used by doctors and researchers to assess how a patient's disease is progressing, 
assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and 
prognosis. They are included here for health care professionals to access. 
ECOG PERFORMANCE STATUS*
Grade ECOG
0 Fully active, able to carry on all pre-disease performance wit hout restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature, e.g., light house work, office work
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and 
about more than 50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5D ead
Protocol Amendment No.: 07
Date: 13-Nov-2020 124
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
APPENDIX 7 RECIST 1.1 GUIDELINES 
1 EVALUATION OF LESIONS
Solid tumors will be evalu ated using Response Evaluation Criteria In Solid Tumors version 1.1 
(RECIST 1.1) guideline .1
At baseline, tumor lesions/lymph nodes will be categorized as m easurable or non-measurable as 
follows:
1.1 Measurable
Tumor lesions: Must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:
10 mm by CT/MRI scan (scan slice thickness no greater than 5 mm) , or≥2x slice thickness if 
greater than 5mm.
Malignant lymph nodes: To be considered pat hologically enlarged and measurable, a lymp h node 
must be ≥15 mm in short axis when assessed by CT/MRI scan (scan slice thi ckness recommended 
to be no greater than 5 mm).
Lymph nodes merit special mention since they are normal anatomical structures which may be 
visible by imaging even if not involved by tumor. Pathological nodes which are defined as 
measurable and may be identified as target lesions must meet th e criterion of a short axis of 
≥15 mm by CT/MRI scan. Onl y the short axis of these nodes will con tribute to the baseline sum. 
The short axis of the node is the diameter normally used by rad iologists to judge if a node is 
involved by solid tumor. Nodal size is normally reported as two  dimensions in the plane in which 
the image is obtained (for CT scan this is almost always the ax ial plane; for MRI the plane of 
acquisition may be axial, sagittal or coronal). The smaller of these measures is the short axis. For 
example, an abdominal node which is reported as being 20 mm x 3 0 mm has a short axis o f 20 mm 
and qualifies as a malignant, measurable node. In this example,  20 mm should be recorded as the 
node measurement. All other pat hological nodes (those with shor t axis ≥10 mm but < 15 mm) 
should be considered non-target lesions. Nodes that have a shor t axis < 10 mm are considered 
non-pathological and should not be recorded or followed.
Note: Lesions on X-Ray are not to be selected as Target or Non- Target Lesions.
1.2 Non-Measurable
All other lesions are considered non-measurable, including smal l lesions (l ongest d iameter 
< 10mm or pathological lymph nodes with ≥10 to < 15 mm short axis) as w ell as truly 
non-measurable lesions. Lesions considered truly non-measurable  include: leptomeningeal 
disease, inflammatory breast disease, lymphangitic involvement of skin or lung, abdominal 
masses/abdominal organomegaly identified by physical exam that is not measurable by 
reproducible imaging techniques.
Note: Lesions on X-Ray are not to be selected as Target or Non-Target Lesions.
Protocol Amendment No.: 07
Date: 13-Nov-2020 125
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
1.3 Special considerations regarding lesion measurability
1.3.1 Bone lesions
•Bone scan, PET scan and plain films are notconsidered adequate imaging techniques to 
measure bone lesions. However, these techniques can be used to confirm the presence or 
disappearance of bone lesions. 
•Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components , that 
can be evaluated by cross sectional imaging techniques such as CT or MRI can be considered 
as measurable lesions if the soft tissue component meets the definition of measurability 
described above.
•Blastic bone lesions are non-measurable.
1.4 Baseline Documentation Of ‘Target’ And ‘Non-Target’ Lesions
When more than one meas urable lesion is present at baseline all  lesions up to a maximum of five 
lesions total (and a maximum of two lesions per organ) represen tative of all involved organs should 
be identified as target lesions and will be recorded and measured at baseline (this means in 
instances where patients have only one or two organ sites invol ved a maximum of two and four 
lesions respectively will be recorded).
Note: A maximum of two lesions can be selected per organ system . For example, a maximum of 
two lung lesions can be selected (selected from one lung or one  lesion from each). A maximum of 
two lymph nodes can be selected at baseline, as the lymphatic system is considered one organ.Target lesions shoul d be selected on the basis of their size (l esions with the longest diameter), be 
representative of all involved organs, but in addition should b e those that lend themselves to 
reproducible repeated measurements. It may be the case that, on  occasion, the largest lesion does 
not lend itself to reproducible measurement in which circumstanc e the next largest lesion which 
can be measured reproducibly should be selected.A sum of the diameters (longest for non-nodal lesions, short ax is for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diam eters. If lymph nodes are to be 
included in the sum, then as noted above, only the short axis i s added into the sum. The baseline 
sum diameters will be used as reference to further characterize  any objective tumor regression in 
the measurable dimension of the disease.All other lesions (or sites of disease) including pathological lymph nodes s hould be identified as 
non-target lesions and should also be recorded at baseline. Mea surements are not required and 
these lesions should be followed as ‘present’, ‘absent’, or in rare cases ‘unequivocal progression’ 
(more details to follo w). In addition, it is  possible to record  multiple non-target lesions involving 
the same organ as a single item on the case record form (eg, ‘multiple en larged pelvic lymph nodes’ 
or ‘multiple liver metastases’).
Protocol Amendment No.: 07
Date: 13-Nov-2020 126
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
2 RESPONSE CRITERIA
2.1 Evaluation of Target Lesions
•Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nod es 
(whether target or non-target) must have reduction in short axi s to < 10 mm.
•Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesio ns, 
taking as reference the baseline sum diameters.
•Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesio ns, 
taking as reference the smallest sum on study (this includes th e baseline sum if that is the 
smallest on study). In addition to the relative increase of 20% , the sum must also demonstrate 
an absolute increase of at least 5 mm. (Note: the appearance of  one or more new lesions is also 
considered progression).
•Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient i ncrease to 
qualify for PD, taking as reference the smallest sum diameters while on study.
•Not Evaluable (NE): If one or more target lesions cannot be measured or adequately assessed 
as either fully resolved or too sm all to measure (due to missi ng or poor quality i mages), and 
the sum of diameters of the remaining measured target lesions ( if any) has not increased 
sufficiently to meet Progressive Disease as defined above. 
2.1.1 Special Notes on the Assessment of Target Lesions
2.1.1.1 Lymph nodes
Lymph nodes identified as target lesions s hould always have the actual short axis measurement 
recorded (measured in the same anatomical plane as the baseline  examination), even if the nodes 
regress to below 10 mm on study. This means that when lymph nod es are included as target lesions, 
the ‘sum’ of lesions may not be zero even if complete response criteria are met, since a normal 
lymph node is defined as having a short axis of < 10 mm. Case r eport forms or other data collection 
methods may therefore be designed to have target nodal lesions recorded in a s eparate section 
where, in order to qualify for CR, each node must achieve a shor t axis < 10 mm. For PR, SD and 
PD, the actual short axis measurement of the nodes is to be included in the sum of target lesions.
2.1.1.2 Target lesions that become ‘too small to measure’
While on study, all lesions (nodal and non-nodal) r ecorded at baseline s hould have their actual 
measurements recorded at each subsequent evaluation, even when very small (eg, 2 mm). 
However, sometimes lesions or lymph nodes which are recorded as  target lesions at baseline 
become so faint on CT scan that the radiologist may not feel co mfortable assigning an exact 
measure and may report them as being ‘too small to measure’. Wh en this occurs it is important 
that a value be recorded on the case report form. If it is the opinion of the radiologist that the lesion 
has likely disappeared, the meas urement should be recorded as 0  mm. If the lesion is believed to 
be present and is faintly seen but too small to measure, a defa ult value of 5 mm should be assigned
as the reference diameter. (Note: It is less likely that this rul e will be used for lymph nodes since 
they usually have a definable size when normal and are frequent ly surrounded by fat such as in the 
retroperitoneum; however, if a lymph node is believed to be pre sent and is faintly seen but too 
Protocol Amendment No.: 07
Date: 13-Nov-2020 127
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
small to measure, a default value of  5 mm s hould be assigned in this circumstance as well). This 
default value is derived from the 5 mm CT slice thickness (but should not be changed with varying 
CT slice thickness). The measurement of these lesions is potent ially non-reprodu cible, therefore 
providi ng this default value will prevent false responses or progressions based upon measurement 
error. To reiterate, however, if the radiologist is able to pro vide an actual meas ure, that should be 
recorded, even if it is below 5 mm.
2.1.1.3 Lesions that split or coalesce on treatment
When non-nodal lesions ‘fragment’, the longest diameters of the  fragmented portions should be 
added together to calculate the target lesion sum. Similarly, a s lesions coalesce, a plane between 
them may be maintained that would aid in obtaining maximal diam eter measurements of each 
individual lesion. If the lesions have truly coalesced such tha t they are no longer separable, the 
vector of the longest diameter in this instance should be the m aximal longest diameter for the 
‘coalesced lesion’.
2.2 Evaluation of Non-Target Lesions
This section provides the definitions of the criteria used to d etermine the tumor response for the 
group of non-target lesions. While some non-target lesions may actually be measurable, they need 
not be measured and instead should be assessed only qualitative ly at the time points specified in 
the protocol.
•Complete Response (CR): Disappearance of all non-target lesions. All lymph nodes must b e 
non-pathological in size (< 10mm short axis). 
•Non-CR/Non-PD: Persistence of one or more non-target lesion(s)
•Progressive Disease (PD): Unequivocal progression of existing non-target lesions.
2.2.1 Special Notes on Assessment of Progression of Non-Target Disease
The concept of progression of non-targ et disease requires addit ional explanation as follows:
2.2.1.1 When the patient also has measurable diseaseIn this setti ng, to achieve ‘unequi vocal progression’ on the basis of the no n-target disease, there 
must be an overall level of subs tantial worsening in non-target disease such that, even in presence 
of SD or PR in target disease, the overall tumor burden has inc reased sufficiently to merit 
discontinuation of therapy A modest ‘increase’ in the size of o ne or more non-target lesions is 
usually not sufficient to qualify for unequivocal progression status. Pleural effusions, pericardial 
effusions and ascites will not be  followed as target or non-tar get lesions and will not contribute to 
response or progression. The designation of overall progression solely on the basis of change in 
non-target disease in the face of SD or PR of target disease wi ll therefore be extremely rare.
2.2.1.2 When the patient has only non-measurable disease
This circumstance arises in some trials when it is not a criter ion of study entry to have measurable 
disease. The same general concepts apply here as noted above, h owever, in this instance there is 
no measurable disease assessment to factor into the inte rpretati on of an increase in non- measurable 
Protocol Amendment No.: 07
Date: 13-Nov-2020 128
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
disease burden. Because worsening in non-target disease ca nnot be easil y quantified (by definition: 
if all lesions are truly non-measurable) a useful test that can  be applied when assessing patients for 
unequivocal progressi on is to consider if the increase in overall disease burden based on the change 
in non-measurable disease is comparable in magnitude to the inc rease that would be required to 
declare PD for measurable disease: ie, an increase in tumor bur den representing an additional 73% 
increase in ‘volume’ (which is equivalent to a 20% increase dia meter in a measura ble lesion). 
Examples include, an increase in lymphangitic disease from loca lized to widespread, or may be 
described as ‘sufficient to require a change in therapy’. If ‘u nequivocal progression’ is seen, the 
patient should be considered to have had overall PD at that poi nt. While it would be ideal to have 
objective criteria to apply to non-measurable disease, the very  nature of that disease makes it 
impossible to do so; therefore the increase must be substantial .
2.2.2 New Lesions
The appearance of new malignant lesions denotes disease progres sion; therefore, some comments 
on detection of new lesions are important. There are no specifi c criteria for the identification of 
new radiographic lesions; however, the finding of a new lesion s hould be unequivocal: ie, not 
attributable to differences in scanning technique, change in im aging modality or findings thought 
to represent something other than tumor (for example, some ‘new ’ bone lesions may be simply 
healing or flare of pre-existing lesions). This is particularly  important when the patient’s baseline 
lesions show partial or complete response. For example, necrosi s of a liver lesion may be reported 
on a CT scan report as a ‘new’ cystic lesion, which it is not.
NOTE: Fluid collections (pleural effusions, pericardial effusio ns, and ascites) will not be 
considered new lesions and will not contribute to response or p rogression. In the event a new fluid 
collection is seen on a post-baseline imagi ng exam, a comment m ay be made, but the appearance 
of a new fluid collection alone should not result in an assessm ent of Progressive Disease (PD). A 
lesion identified on a follow-up study in an anatomical locatio n that was not scanned at baseline 
is considered a new lesion and will indicate disease progressio n. An example of this is the patient 
who has visceral disease at baseline and while on study has a CT or MRI brain ordered which 
reveals metastases. The patient’s brain metastases are consider ed to be evidence of PD even if 
he/she did not have brain imaging at baseline. A lesion identifi ed on Chest X-Ray that was not 
present in prior CT can be considered a new lesion and will res ult in Progressive Disease (PD).
If a new lesion is equivocal, for example because of its small size, continued follow-up evaluation 
will clarify if it represents truly new disease. If repeat scans con firm there is definitely a new 
lesion, then progression should be  declared using the date of t he initial scan. While FDG-PET 
response assessments need additi onal study, it is sometimes rea sonable to incorporate the use of 
FDG-PET scanning to complement CT scanning in assessment of pro gression (particularly 
possible ‘new’ disease). New lesions on the basis of FDG-PET im aging can be identified according 
to the following algorithm:1. Negative FDG-PET at baseline, with a positive FDG-PET at foll ow-up is a sign of PD based 
on a new lesion.
Protocol Amendment No.: 07
Date: 13-Nov-2020 129
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
2. No FDG-PET at baseline and a positive FDG-PET at follow-up: I f the positive FDG-PET at 
follow-up corresponds to a new site of disease confirmed by CT,  this is PD. If the positive 
FDG-PET at follow-up is not confirmed as a new site of disease on CT, additional follow-up 
CT scans are needed to determine if there is truly progression occurring at that site (if so, the 
date of PD will be the d ate of the initial a bnormal FDG-PET scan). If the positive FDG-PET 
at follow-up corresponds to a pre-existing site of disease on C T that is not progressing on the 
basis of the anatomic images, this is not PD.
2.3 Response Assessment
2.3.1 Evaluation of Best Overall Response
The best overall response is the best response recorded from th e start of the study treatment until 
disease progression or th e last response recorded, taking into account any requirement for 
confirmation and censoring rules regarding subsequent therapy. T he patient’s best overall res ponse 
assignment will depend on the findings of both target and non-target disease and will also take into 
consideration the appearance of new lesions. Furthermore, depen ding on the nature of the study 
and the protocol requirements , it may also require confirmatory  measurement.
2.3.2 Time Point Response
At each protocol specified time point, a response assessment occurs. Table 2.3.2-1 provides a 
summary of the overall re sponse status calculation at each time point for patients who have 
measurable disease at baseline. When patients have non-measurab le (therefore non-target) disease 
only,  Table 2.3.2-2 is to be used. 
Table 2.3.2-1: Time Point Response: Patients With Target (± Non- Target) Disease
Target Lesions Non-Target Lesions New Lesions Overall Response
CR CR No CR
CR Non-CR/non-PD No PR
CR Not evaluated No PR
PRNon-PD or not all 
evaluatedNo PR
SDNon-PD or not all 
evaluatedNo SD
Not all evaluated Non-PD No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
CR = complete response, PR = partial response, SD = stable dise ase, PD = progressive disease and NE = inevaluable
Protocol Amendment No.: 07
Date: 13-Nov-2020 130
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Table 2.3.2-2: Time Point Response: Patients with Non-target Dis ease Only
Non-Target Lesions New Lesions Overall Response
CR No CR
Non-CR/non-PD No Non-CR/non-PDa
Not all evaluated No NE
Unequivocal PD Yes or No PD
Any Yes PD
CR = complete response, PD = progressive disease and NE = inevaluable
aNon-CR/non-PD is preferred over SD for non-target disease since  SD is increasingly used as endpoint for 
assessment of efficacy in some trials so to assign this categor y when no lesions can be measured is not advised.
2.3.3 Best Overall Response 
Best response determinati on of complete or par tial res ponse requires confirmation: Complete or 
partial responses may be claimed only if the criteria for each are met at a subsequent time point of 
≥4 weeks (28 days) later. In this circumstance, the best overall  response can be interpreted as in 
Table 2.3.3-1.  When SD is believed to be best response, it must meet the prot ocol specified 
minimum time from the d ate of first treatment or randomization d ate.
For example, if the first scheduled follow-up imaging visit is Week 6 ( ±7 days) for a particular 
protocol, a Best Response of SD ca n only be made after the part icipant is on-study for a minimum 
of 6 weeks (42 days) minus 7 days, for an absolute minimum time  on-study of 35 days from the 
reference start date (reference date is considered Day 1 on stu dy).  If the participan t is not on-study 
for at least this am ount of t ime, any tumor assessment indicating stable disease before this  time 
period will have a Best Response of NE unless PD is identified.
Special note on response assessment: When nodal disease is included in the sum of target lesions 
and the nodes decrease t o ‘normal’ s ize (< 10 mm), they may st ill have a measurement reported 
on scans. This measurement should be recorded even though the nodes are normal in order not to 
overstate progression should it be based on increase in size of  the nodes. As noted earlier, this 
means that patients with CR may not have a total sum of ‘zero’ on the case report form (CRF).
Table 2.3.3-1: Best Overall Response (Confirmation of CR and PR R equired)
Overall Response 
First Time PointOverall Response 
Subsequent Time PointBest Overall Response
CR CR CR
CR PR SD, PD OR PRa
CR SDSD provided minimum criteria for SD duration met, otherwise, 
PD
CR PDSD provided minimum criteria for SD duration met, otherwise, PD
Protocol Amendment No.: 07
Date: 13-Nov-2020 131
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Table 2.3.3-1: Best Overall Response (Confirmation of CR and PR R equired)
Overall Response 
First Time PointOverall Response 
Subsequent Time PointBest Overall Response
CR NESD provided minimum criteria for SD duration met, otherwise, 
NE
PR CR PR
PR PR PR
PR SD SD
PR PDSD provided minimum criteria for SD duration met, otherwise, 
PD
PR NESD provided minimum criteria for SD duration met, otherwise, NE
NE NE NE
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, and 
NE = inevaluable
aIf a CR is truly met at first time point, then any disease seen  at a subsequent time point, even disease meeting PR 
criteria relative to baseline, makes the disease PD at that point (since disease must have reappeared after CR). Best 
response would depend on whether minimum duration for SD was me t. However, sometimes ‘CR’ may be claimed 
when subsequent scans suggest small lesions were likely still present and in fact the patient had PR, not CR at the first time point. Under these circumstances, the original CR sh ould be changed to PR and the best response is PR.
2.3.4 Confirmation Scans
Verification of Response: To be assigned a status of CR or PR, changes in tum or measurements 
must be confirmed by consecutive or subsequent repeat assessment s that should be performed no 
less than 28 days after the criteria fo r response are first met. Subsequent documentation of a CR 
may provide confirmation of a previously identified CR even with  an intervening NE or PR (eg, 
CR NE CR or CR PR CR). Subsequent documentation of a PR may provi de confirmation of a
previously identified PR even with an intervening NE or SD (eg,  PR NE PR or PR SD PR). 
However, only one (1) intervening time point will be allowed between PR/CRs for confirmation.
Verification of Progression : Progressi on of disease should be verified in cases where progression 
is equivocal. If repeat scans confirm PD, then progression should be declared using the date of the 
initial scan. If rep eat scans do not confirm PD, then the participant is considered to not have 
progressive disease.
Protocol Amendment No.: 07
Date: 13-Nov-2020 132
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 133
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 134
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 13-Nov-2020 135
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
APPENDIX 10 COUNTRY SPECIFIC APPENDIX
Table 1: Criteria for exclusion of HIV-positive participants in Germany and
other countries as applicable
Section 6.2 Exclusion Criteria,
Exclusion criterion 4) Physical and Laboratory Test 
Findings, l)“Known history of positive test for human
immunodeficiency virus (HIV) or known acquired
immunodeficiency syndrome (AIDS)”to be replaced with
“Positive test for HIV”.
Section 2 Flow Chart/Time and Events Schedule,
Table 2- 1 : Screening Assessments- Laboratory
TestsAdd “HIV” to the list of laboratory tests
Protocol Amendment No.: 07
Date: 13-Nov-2020 136
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
APPENDIX 11 REVISED PROTOCOL SUMMARY OF CHANGE HISTORY
 Revised Protocol 06, 02-Jun-2020
 
 
 
 
 
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 06
Section Number & 
TitleDescription of Change Brief Rationale
•Synopsis: Overall 
Design 
•Section 5.1 Overall Design 
•Section 5.1 Overall Design, Treatment Phase
•Section 7.1 Treatments AdministeredText has been added to clarify that
treatment with SOC may continue, 
after the maximum treatment duration of 24 months for nivolumab, until progression, unacceptable toxicity, withdrawal of consent, or the end of the study, whichever comes first.Clarification for study sites that 
treatment with SOC may continue, 
after the maximum treatment duration of 24 months for nivolumab, until progression, unacceptable toxicity, withdrawal of consent, or the end of the study, whichever comes first, which is consistent with NCCN guidelines for 
1L treatment for mCRC.
Throughout Minor editorial or format changes that do not change content.Clarify text. 
 Revised Protocol 05, 19-Dec-2019
 
 
SUMMARY OF KEY CHANGES
OF REVISED PROTOCOL 05
Section Number & 
TitleDescription of Change Brief Rationale
Synopsis; Section 5, Overall 
Study DesignUpdated Figure and footnotes, and 
description of analyses to remove 
reference of IA2.As described in the overall rationale.
Section 2, Schedule of 
Activities, Table 2- 2, On-
Treatment Procedural 
Outline, CEA (and CA19-9) 
AssessmentCollection window (± 7 day) added.This collection is intended to align with 
tumor assessments, therefore the 7 day 
window as added as clarification.
Section 10.3.4, Interim 
AnalysesUpdated to remove reference to IA2. As described in the overall rationale
Protocol Amendment No.: 07
Date: 13-Nov-2020 137
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 05
Section Number & 
TitleDescription of Change Brief Rationale
Appendix 5Management Algorithms Updated. 
Myocarditis Algorithm added.Algorithms have been updated to 
contain the most recent version from 
the 27-Jun-2019 IB. The only update to 
the algorithms in the latest IB is 
addition of the myocarditis algorithm.
 Revised Protocol 04, 07-Dec-2018
 
 
Summary of key changes of Revised Protocol 04
Section Number 
& TitleDescription of Change Brief Rationale
Section 2, Schedule 
of Activities, Table 
2-2, On-Treatment 
Procedural Outline 
(CA2099X8), IRT 
Vial Assignment, 
Fluorouracil 1200 mg 
and 2400 mg 
infusionsRevised Notes regarding schedule of fluorouracil 
infusion.To clarify the fluorouracil 
infusion days.
Section 7.1, 
Treatments 
Administered, Table 
7.1-1, Section and 
Timing of Dose, 
Fluorouracil 1200 mg
and 2400 mg 
infusions; 
paragraph e, under 
Nivolumab plus SOC 
and bevacizumab 
arm; and paragraph 2 
under SOC and 
bevacizumab arm.Revised text regarding schedule of fluorouracil 
infusion.To clarify the fluorouracil 
infusion days.
Section 7.1, 
Treatments 
AdministeredParagraph 8 was revised and paragraph 9 was 
removed.Detailed text regarding 
treatment administration of 
nivolumab is addressed in the 
Pharmacy Manual.
Appendix 3 Revised text in the following sections: Events 
Meeting the AE Definition, Events Not Meeting the Updated to reflect the most 
recent language for BMS 
studies.
Protocol Amendment No.: 07
Date: 13-Nov-2020 138
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Summary of key changes of Revised Protocol 04
Section Number 
& TitleDescription of Change Brief Rationale
AE Definition, Definition of SAE, and Follo w-up of 
AEs and SAEs.
Appendix 4 Removed text regarding women treated with 
hormone replacement therapy. 
Revised text regarding highly effective methods of 
contraception that are user independent and 
unacceptable methods of contraception. Update to Appendix 4 in the 
previous version was incorrect. 
The current version has been updated to align with contraceptive guidance for participants being treated with nivolumab and other components of study treatment.
 Revised Protocol 03, 13-Sep-2018
 
Summary of key changes of Revised 
Protocol 03
Section Number & 
TitleDescription of Change Brief Rationale
Section 6.2, Exclusion 
Criteria, 2), j)Exclusion criteria removed in 
Revised Protocol 02, has been 
returned to the document. Feedback from  requested we reinstate 
exclusion criteria 2j, due to concerns of GI 
perforation highlighted in the Avastin black box 
warning.
 Revised Protocol 02, 06-Aug-2018
 
Summary of key changes of Revised 
Protocol 02
Section Number & Title Description of Change Brief Rationale
Section 2, Schedule of Activities, 
Table 2-1;  Section 5.1, Overall 
Design, Screening Phase, 
Participants must submit mandatory 
baseline tumor sample, bullet Regarding baseline tumor submission, 
text was deleted regarding tissue 
submission from a resected primary 
tumor, archival tissue from an 
endoscopic biopsy, or baseline tumor Language removed to clarify 
that tissue from the primary 
tumor will be required in order 
to enroll in this study, without 
exception.
Protocol Amendment No.: 07
Date: 13-Nov-2020 139
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Summary of key changes of Revised Protocol 02
Section Number & Title Description of Change Brief Rationale
2;Section 6.1, Inclusion Criteria 
2) Type of Participant and Target 
Disease Characteristics e) ii)submission that occurred 6 or more 
years prior to randomization.
Section 2, Schedule of Activities, 
Table 2-1Regarding laboratory tests, a note was 
added stating that laboratory tests do 
not need to be repeated on C1D1 if 
screening laboratory results are 
deemed still clinically valid by the 
treating investigator.In alignment with other 
protocols, to provide reasonable 
flexibility to sites and subjects 
in terms of timing of lab test 
blood draws 
Section 2, Schedule of Activities, 
Table 2-1, Footnote b; Table 2-2, 
Footnote d, and Table 2-3, 
Footnote d.Footnote was revised to allow for 
urine protein to creatinine ratio 
(UPCR) in place of the 24-hour urine 
collection.Urine protein to creatinine ratio 
is an acceptable method to 
assess and manage proteinuria 
and less cumbersome as a 24-hr 
urine collection.
Section 2, Schedule of Activities, 
Table 2-2Regarding IRT vial assignment, timing 
of fluorouracil was revised.To clarify the schedule of 5-FU 
infusion.
Section 2, Schedule of Activities, 
Table 2-2Table footnote b includes revised dose 
delay information.  
 
 Added 
text to clarify that CEA and 
CA19-9 should be collected on 
schedule regardless of dose 
delays.
Protocol Amendment No.: 07
Date: 13-Nov-2020 140
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Summary of key changes of Revised Protocol 02
Section Number & Title Description of Change Brief Rationale
Section 6.1, Inclusion Criteria, 2) c) 
iRevised language for time gap 
between the completion of adjuvant or 
neoadjuvant chemotherapy and 
diagnosis of recurrent or metastatic 
disease.Clarification of eligibility 
criteria.
Section 6.1, Inclusion Criteria, 2) hCriterion was added to require that all 
participants will be required to 
undergo on-treatment biopsies.Added with the addition of 
mandatory on-treatment 
biopsies.
Section 6.1, Inclusion Criteria, 3) d) 
and f Revised the time from last dose of 
investigation drugUpdated to reflect the most 
recent language for BMS 
studies.
Section 6.2, Exclusion Criteria, 2) 
Medical ConditionsCriterion g was revised to within 6 
months of enrollment.
Criterion j is no longer applicable.Modified to align with clinical 
practice.
Section 6.2, Exclusion Criteria, 
3) Prior/Concomitant TherapyRevised criterion c.To align with current 
bevacizumab label.  The current 
label states that bevacizumab 
should be discontinued at least 
28 days prior to surgery, and 
should be held for at least 28 
days after surgery.
Section 6.2, Exclusion Criteria, 
3) Prior/Concomitant TherapyAdded criterion 3f to exclude 
participants who have received a live / 
attenuated vaccine within 30 days of 
first treatment.Alignment with current BMS 
standards for studies using 
nivolumab.
Section 6.2, Exclusion Criteria, 
Physical and laboratory test 
findings; and Section 9.4.3, Clinical 
Safety Laboratory Assessments Criterion 4j revised to include a 
statement to allow for urine protein to 
creatinine ratio in place of the 24-hour 
urine collectionUrine protein to creatinine ratio 
is an acceptable method to 
assess and manage proteinuria 
and less cumbersome as a 24-hr 
urine collection
Section 7, Treatment; Table 7.1-1; 
section on Nivolumab plus SOC and 
bevacizumab armAdded text regarding dosing 
calculations to Table 7.1-1; 
paragraph 3 under the section titled, 
Nivolumab plus SOC and To clarify the dose and the 
schedule of 5-FU infusion.
Protocol Amendment No.: 07
Date: 13-Nov-2020 141
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Summary of key changes of Revised Protocol 02
Section Number & Title Description of Change Brief Rationale
bevacizumab arm; and paragraph 3 
under the section titled, SOC and 
bevacizumab arm.
Section 7, TreatmentBelow paragraph 8, a paragraph was 
added regarding dosing calculations
for bevacizumab administration.To clarify that weight based 
dosing does not need to be 
recalculated if the patient’s 
weight is within 10% of the 
weight used to calculate the 
previous dose.
Section 7.4.4, Table 7.4.4-1Revisions were made to the 
recommended guidelines for 
management of proteinuria.To include information on urine 
protein to creatinine ratio  
Section 7.7.1, Prohibited and/or 
Restricted TreatmentsAdded a new bullet to prohibit 
administration of any live / attenuated 
vaccine (eg varicella, zoster, yellow 
fever, rotavirus, oral polio and 
measles, mumps, rubella [MMR]) 
during treatment and until 100 days 
post last dose. Alignment with current BMS 
standards for studies using 
nivolumab.
Section 8.1.1, Nivol umab Dose 
DiscontinuationMyocarditis added to the list of drug-
related events requiring 
discontinuation.Update to be consistent with 
SmPC and the label for 
nivolumab. 
Section 8.1.2, SOC Dose 
DiscontinuationRevised bullet items for bevacizumab
discontinuations.To align with current 
bevacizumab label.
Section 9.2.5, PregnancyAdded paragraph regarding possible 
pregnancy.Updated to reflect the most 
recent language for BMS 
studies. 
Section 9.3, Overdose Revised reporting text.Updated to reflect the most 
recent language for BMS 
studies.
Section 9.4.3, Clinical Safety 
Laboratory Assessments, Other 
AnalysesAdded CEA and CA19-9 testingTo be consistent with section 2, 
schedule of activity. 
Protocol Amendment No.: 07
Date: 13-Nov-2020 142
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Summary of key changes of Revised Protocol 02
Section Number & Title Description of Change Brief Rationale
Appendix 2, Study Governance 
ConsiderationsMinor revisions to language Good 
Clinical Practice potential serious 
breach reporting.
Deleted return of study treatment 
language that specified study 
treatments supplied by BMS or its 
vendors.Updated to reflect the most 
recent language for BMS 
studies.
Appendix  3, Adverse Events and 
Serious Adverse Events: Definitions 
and Procedures for Recording, 
Evaluating, Follow Up and 
ReportingAdded sections: Events Meeting the 
AE Definitions and Events NOT 
Meeting the AE Definition; and 
Definition of SAE 
Revised text regarding pregnancy and 
potential drug induced liver injury.
Revised text for the following: 
Evaluating AEs and SAEs, 
Assessment  of Causality, Follow-up of 
AE and SAEs; Reporting of SAEs to 
Sponsor or Designee.Updated to reflect the most 
recent language for BMS 
studies.
Appendix 4, Women of 
Childbearing Potential Definitions 
and Methods of ContraceptionAdded note regarding women treated 
with hormone replacement therapy.
Revised the definition relevant 
systemic exposure.
Revised text regarding highly effective 
methods of contraception that are user 
independent.
Revised section on unacceptable 
methods of contraception to include 
section on less than highly effective 
contraceptive methods that are user 
dependent.Updated to reflect the most 
recent language for BMS 
studies.
Appendix 5, Hepatic Adverse Event 
Management AlgorithmFootnote *, regarding delay of I-O 
therapy was deleted.Hepatic algorithm updated to 
align with most recent guidance 
in the IB.
Appendix 10, Country Specific 
AppendixAdded additional countries as 
applicable.Updated to reflect the most 
recent language for BMS 
studies.
AllMinor formatting and typographical 
corrections.Minor, therefore have not been 
summarized
Protocol Amendment No.: 07
Date: 13-Nov-2020 143
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
 Revised Protocol 01, 02-Feb-2018
 
 
 
 
 
 
 
 
Summary of key 
changes of Revised Protocol 01
Section 
Number & TitleDescription of Change Brief Rationale
2, Schedule of 
Activities, Tables 2-
1, 2-2, 2-3Addition of urinalysis requirementsTo ensure assessment of proteinuria at 
screening and management of 
proteinuria during and after treatment 
6.1 Inclusion 
Criteria, 2) Type of 
Participant and 
Target Disease 
Charact.eristicsInclusion criteria 2.b rephrasedInclusion criteria reworded for better 
clarity
6.1 Inclusion 
Criteria, 2) Type of Inclusion criteria 2.c.i updatedInclusion criteria updated to allow 
participants who had neoadjuvant 
Protocol Amendment No.: 07
Date: 13-Nov-2020 144
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Summary of key changes of Revised Protocol 01
Section 
Number & TitleDescription of Change Brief Rationale
Participant and 
Target Disease 
Charact.eristicschemotherapy to be eligible, if > 6 
months have elapsed since completion 
of that therapy and diagnosis of 
recurrent or metastatic disease
6.1 Inclusion 
Criteria, 2) Type of 
Participant and 
Target Disease 
Charact.eristicsInclusion criteria 2.e rephrasedSentence added to specify that adequate 
tumor tissue must be available for 
eligibility
6.2 Exclusion 
Criteria, 2) Medical 
ConditionsExclusion criteria 2 k updated Clarifies half-teaspoon volume
6.2 Exclusion 
Criteria, 2) Physical 
and Laboratory Test 
FindingsExclusion criteria 4.g and 4.j updatedClarifies AST/ALT exclusion criteria 
for participants with  liver metastases 
and eligibility requirements for 
proteinuria
6.3 Lifestyle 
RestrictionsLifestyle restrictions updatedSpecifies that there may be restrictions 
associated to the SOC components
7.4 Dosage 
Modification4th bullet addedBullet added to specify that if there is a 
delay in administration of study drug(s) due to toxicity, treatment with the other 
study agent(s) should continue as 
scheduled and resumption of treatment 
should be at the next scheduled time 
point
7.4.1 Nivolumab 
Dose DelayLast paragraph updated with guidelines on what 
to do with other study agents in case of 
nivolumab dose delayClarifies what to do with other study 
agents in case of nivolumab delay.
7.4.4 Dose 
Modification 
Criteria for 
bevazicumabDose modification criteria updated with 
recommended guidelines for the management 
of proteinuriaBevacizumab may be discontinued 
without other study drugs needing to be 
discontinued. 
7.7.1 Prohibited 
and/or Restricted 
TreatmentRestrictions on botanical preparation updated 
with conditions of use of marijuana and its 
derivativesUnder certain conditions use of 
marijuana and its derivatives will be 
permitted in this protocol as per latest 
BMS standards
7.7.1 Prohibited 
and/or Restricted 
TreatmentOngoing treatment with aspirin (>325 mg/day) 
or other medications known to predispose 
participants to gastrointestinal ulceration and 
reference to local institutional standards and 
product labels of SOC components added to the 
list of prohibited/restricted treatmentsRestriction on aspirin treatment or 
medications known to predispose 
participants to gastrointestinal 
ulceration added specifically for 
bevacizumab treatment. Reference to 
institutional standards or product labels 
added for clarity.
Protocol Amendment No.: 07
Date: 13-Nov-2020 145
Approved 9.0 v
Approved
1.0
v

Clinical Protocol CA2099X8
BMS-936558 nivolumab
Summary of key changes of Revised Protocol 01
Section 
Number & TitleDescription of Change Brief Rationale
8.1 Discontinuation 
from Study 
TreatmentThird paragraph related to discontinuation 
guidelines in case of pregnancy revisedUpdated as per latest BMS standard 
language. In case of pregnancy, study 
treatment must be discontinued. 
Conditions to restart study treatment 
have been clarified.
8.1.2 SOC Dose 
DiscontinuationDiscontinuation criteria list for SOC drugs 
updatedClarifies that certain criteria for 
discontinuation must be drug related 
and list of bevacizumab discontinuation 
criteria updated to better align with 
bevacizumab label
8.1.3 Last bullet added to specify when to resume 
treatmentLast bullet specifies that resumption of 
treatment should be at the next 
scheduled time point
9.2.7 Potential Drug 
Induced Liver 
Injury (DILI)Section updated with definition of DILI for 
participants with elevated AST, ALT or Total 
Bilirubin at baselineDefinition of DILI updated in order to 
take into account potential participants 
enrolled with elevated liver function 
tests
9.4.3 Clinical Safety 
Laboratory 
AssessmentsGlucose fasting status updated, coagulation 
testing (PT/INR) updated to be performed if 
clinically indicated, urinalysis testing updated 
as per updated schedule of activities (section 2)Fasting status for glucose clarified as 
not mandatory, coagulation testing may 
be performed during bevacizumab 
treatment if clinically indicated, 
urinalysis testing requirements updated 
for proteinuria assessment and 
management
Throughout 
protocolTypographical, formatting and wording updatesTypographical, formatting and wording 
updates
Protocol Amendment No.: 07
Date: 13-Nov-2020 146
Approved 9.0 v
Approved
1.0
v
